@NP	Effects of human OEC-derived cell transplants in rodent spinal cord	1
@NP	Effects	1
@NP	human OEC-derived cell transplants in rodent spinal cord	12
@NP	human OEC-derived cell transplants	12
@NP	rodent spinal cord	50
@NP	contusion injury	69
@NP	Catherine Anne Gorriea ,	88
@NP	Ian Haywardb	114
@NP	Nicholas Cameronb	128
@NP	Gajan Kailainathana	147
@NP	Neilan Nandapalana	168
@NP	Ratneswary Sutharsanb	188
@NP	Jennifer Wanga	211
@NP	Alan Mackay-Simb	227
@NP	Phil M.E.	245
@NP	Waitea aNeural Injury Research Unit	255
@NP	School of Medical Sciences	292
@NP	School	292
@NP	Medical Sciences	302
@NP	University of New South Wales	320
@NP	University	320
@NP	New South Wales	334
@NP	Sydney	351
@NP	NSW	359
@NP	2052	364
@NP	Australia bNational Centre for Adult Stem Cell Research	370
@NP	Australia bNational Centre	370
@NP	Adult Stem Cell Research	401
@NP	Griffith University	427
@NP	Brisbane	448
@NP	QLD 4111	458
@NP	Australia Abstract Numerous reports	468
@NP	rodent olfactory ensheathing cells -LRB- OECs -RRB-	520
@NP	rodent olfactory ensheathing cells	520
@NP	OECs	556
@NP	spinal cord repair and clinical trials	572
@NP	spinal cord repair	572
@NP	clinical trials	595
@NP	autologous transplantation	638
@NP	human olfactory ensheathing cells -LRB- hOECs -RRB-	668
@NP	human olfactory ensheathing cells	668
@NP	hOECs	703
@NP	a treatment for spinal cord injury	713
@NP	a treatment	713
@NP	spinal cord injury	729
@NP	there	758
@NP	few studies	768
@NP	the efficacy of hOECs in animal models of spinal cord injury	794
@NP	the efficacy	794
@NP	hOECs in animal models of spinal cord injury	810
@NP	hOECs	810
@NP	animal models of spinal cord injury	819
@NP	animal models	819
@NP	spinal cord injury	836
@NP	this study	859
@NP	hOECs	870
@NP	biopsies of human olfactory mucosa	894
@NP	biopsies	894
@NP	human olfactory mucosa	906
@NP	culture	941
@NP	a serum-free medium containing neurotrophin-3	952
@NP	a serum-free medium	952
@NP	neurotrophin-3	983
@NP	EGFP	1025
@NP	These hOEC-derived cells	1050
@NP	the spinal cord injury site 7 days	1109
@NP	the spinal cord injury site	1109
@NP	7 days	1137
@NP	a moderate contusion injury of the spinal cord	1150
@NP	a moderate contusion injury	1150
@NP	the spinal cord	1181
@NP	thoracic level T10 in the athymic rat	1200
@NP	thoracic level T10	1200
@NP	the athymic rat	1222
@NP	Six weeks later	1239
@NP	the animals	1255
@NP	the hOEC-derived transplants	1277
@NP	greater functional improvement	1310
@NP	their hindlimbs	1344
@NP	controls	1365
@NP	open field -LRB- BBB scale -RRB-	1390
@NP	open field	1390
@NP	BBB scale	1402
@NP	tests	1441
@NP	Histological analysis	1448
@NP	beneficial effects of hOEC-derived cell transplantation	1483
@NP	beneficial effects	1483
@NP	hOEC-derived cell transplantation	1505
@NP	reductions in the volume of the lesion	1540
@NP	reductions	1540
@NP	the volume of the lesion	1554
@NP	the volume	1554
@NP	the lesion	1568
@NP	the cavities within the lesion	1583
@NP	the cavities	1583
@NP	the lesion	1603
@NP	The transplanted cells	1615
@NP	the periphery of the lesion	1654
@NP	the periphery	1654
@NP	the lesion	1671
@NP	they	1688
@NP	GFAP-positive astrocytes	1709
@NP	a significant reduction of GFAP staining intensity adjacent to the lesion	1747
@NP	a significant reduction	1747
@NP	GFAP staining intensity adjacent to the lesion	1774
@NP	GFAP staining intensity	1774
@NP	the lesion	1810
@NP	their mechanism of action	1831
@NP	their mechanism	1831
@NP	action	1850
@NP	we	1868
@NP	hOEC-derived cell transplants	1885
@NP	functional recovery	1924
@NP	transplantation	1950
@NP	the	1971
@NP	spinal cord	1984
@NP	inflammatory responses	2020
@NP	secondary damage	2056
@NP	the cord	2076
@NP	Introduction Traumatic spinal cord injury	2090
@NP	Introduction	2090
@NP	Traumatic spinal cord injury	2103
@NP	a complex , progressive event leading to long-term motor and sensory deficits	2135
@NP	a complex , progressive event leading	2135
@NP	long-term motor and sensory deficits	2175
@NP	dysfunction of the autonomic nervous system	2217
@NP	dysfunction	2217
@NP	the autonomic nervous system	2232
@NP	the spinal cord	2265
@NP	there	2281
@NP	cell death	2290
@NP	axons	2314
@NP	demyelination	2321
@NP	inflammation	2336
@NP	the formation of cystic cavities -LRB- Sekhon and Fehlings , 2001 -RRB-	2353
@NP	the formation	2353
@NP	cystic cavities -LRB- Sekhon and Fehlings , 2001 -RRB-	2370
@NP	cystic cavities	2370
@NP	Sekhon and Fehlings	2387
@NP	2001	2408
@NP	There	2415
@NP	limited capacity of the human spinal cord to repair itself	2424
@NP	limited capacity	2424
@NP	the human spinal cord	2444
@NP	itself	2476
@NP	there	2487
@NP	a need for therapeutic strategies to protect and repair the injured spinal cord	2496
@NP	a need	2496
@NP	therapeutic strategies	2507
@NP	the injured spinal cord	2552
@NP	Olfactory ensheathing cells -LRB- OECs -RRB-	2577
@NP	Olfactory ensheathing cells	2577
@NP	OECs	2606
@NP	a unique type	2616
@NP	glial cell	2633
@NP	some properties	2655
@NP	astrocytes and Schwann cells	2676
@NP	intrinsic properties	2714
@NP	them	2745
@NP	ideal candidates for cellular grafts	2750
@NP	ideal candidates	2750
@NP	cellular grafts	2771
@NP	injured spinal tissue	2792
@NP	Chuah and Au	2815
@NP	1994	2829
@NP	Fairless and Barnett , 2005	2835
@NP	Fairless and Barnett	2835
@NP	2005	2857
@NP	Farbman and Squinto , 1985	2863
@NP	Farbman and Squinto	2863
@NP	1985	2884
@NP	Ramon-Cueto and Valverde	2890
@NP	Ramon-Cueto	2890
@NP	Valverde	2906
@NP	1995	2916
@NP	Many studies	2923
@NP	OECs	2959
@NP	the injured spinal cord	3003
@NP	rodent models	3030
@NP	restoration	3054
@NP	motor function	3069
@NP	Keyvan	3085
@NP	Fouladi	3093
@NP	et al. , 2003	3101
@NP	et al.	3101
@NP	2003	3109
@NP	Kubasak et al. , 2008	3115
@NP	Kubasak	3115
@NP	et al. , 2008	3123
@NP	et al.	3123
@NP	2008	3131
@NP	Li et al. , 2003	3137
@NP	Li	3137
@NP	et al. , 2003	3140
@NP	et al.	3140
@NP	2003	3148
@NP	Li et al. , 1997	3154
@NP	Li	3154
@NP	et al. , 1997	3157
@NP	et al.	3157
@NP	1997	3165
@NP	Lopez-Vales et al. , 2007	3171
@NP	Lopez-Vales	3171
@NP	et al. , 2007	3183
@NP	et al.	3183
@NP	2007	3191
@NP	improvement of respiratory function -LRB- Li et al. , 2003 -RRB-	3198
@NP	improvement	3198
@NP	respiratory function -LRB- Li et al. , 2003 -RRB-	3213
@NP	respiratory function	3213
@NP	Li	3235
@NP	et al. , 2003	3238
@NP	et al.	3238
@NP	2003	3246
@NP	restoration of bladder function -LRB- Pascual et al. , 2002 -RRB-	3256
@NP	restoration	3256
@NP	bladder function -LRB- Pascual et al. , 2002 -RRB-	3271
@NP	bladder function	3271
@NP	Pascual	3289
@NP	et al. , 2002	3297
@NP	et al.	3297
@NP	2002	3305
@NP	Most previous studies	3871
@NP	the therapeutic properties of rat OECs	3911
@NP	the therapeutic properties	3911
@NP	rat OECs	3941
@NP	human OECs	3959
@NP	spinal cord axons	3983
@NP	demyelinating lesions -LRB- Barnett et al. , 2000 ; Kato et al. , 2000 -RRB-	4007
@NP	demyelinating lesions	4007
@NP	Barnett	4030
@NP	et al. , 2000 ; Kato et al. , 2000	4038
@NP	et al.	4038
@NP	2000 ; Kato et al.	4046
@NP	2000	4046
@NP	Kato et al.	4052
@NP	Kato	4052
@NP	et al.	4057
@NP	2000	4065
@NP	primate OECs	4075
@NP	locomotor recovery	4096
@NP	transection injury	4121
@NP	the rat -LRB- Guest et al. , 2008 -RRB-	4143
@NP	the rat	4143
@NP	Guest	4152
@NP	et al. , 2008	4158
@NP	et al.	4158
@NP	2008	4166
@NP	There	4173
@NP	no previous studies of human OEC transplantation	4183
@NP	no previous studies	4183
@NP	human OEC transplantation	4206
@NP	the contused rat spinal cord	4237
@NP	a model of injury that mimics aspects of many common human injuries	4267
@NP	a model	4267
@NP	injury	4278
@NP	aspects of many common human injuries	4297
@NP	aspects	4297
@NP	many common human injuries	4308
@NP	Most previous studies , including the human and primate reports ,	4336
@NP	Most previous studies	4336
@NP	the human and primate reports	4369
@NP	OECs	4409
@NP	the olfactory bulbs	4419
@NP	the cranial cavity	4446
@NP	This	4466
@NP	a clinically favoured site	4478
@NP	sourcing autologous OECs	4509
@NP	the morbidity	4545
@NP	surgical access and destruction of the olfactory bulbs	4575
@NP	surgical access and destruction	4575
@NP	the olfactory bulbs	4610
@NP	the cells	4640
@NP	OECs	4651
@NP	the olfactory mucosa in the nose -LRB- Bianco et al. , 2004 -RRB-	4677
@NP	the olfactory mucosa	4677
@NP	the nose -LRB- Bianco et al. , 2004 -RRB-	4701
@NP	the nose	4701
@NP	Bianco	4711
@NP	et al. , 2004	4718
@NP	et al.	4718
@NP	2004	4726
@NP	OECs from this source	4736
@NP	OECs	4736
@NP	this source	4746
@NP	the transected spinal cord in rat -LRB- Lu et al. , 2001 , 2002 -RRB-	4798
@NP	the transected spinal cord	4798
@NP	rat -LRB- Lu et al. , 2001 , 2002 -RRB-	4828
@NP	rat	4828
@NP	Lu	4833
@NP	et al. , 2001 , 2002	4836
@NP	et al.	4836
@NP	2001	4844
@NP	2002	4850
@NP	hOECs derived from the olfactory mucosa	4857
@NP	hOECs	4857
@NP	the olfactory mucosa	4876
@NP	rat nasal OECs in proliferation , survival and migration	4913
@NP	rat nasal OECs	4913
@NP	proliferation , survival and migration	4931
@NP	transplantation	4975
@NP	the normal spinal cord of athymic rats -LRB- Deng et al. , 2006 -RRB-	4996
@NP	the normal spinal cord	4996
@NP	athymic rats -LRB- Deng et al. , 2006 -RRB-	5022
@NP	athymic rats	5022
@NP	Deng	5036
@NP	et al. , 2006	5041
@NP	et al.	5041
@NP	2006	5049
@NP	autologous transplants	5060
@NP	OECs	5084
@NP	the human nose	5124
@NP	biopsy of the olfactory mucosa	5142
@NP	biopsy	5142
@NP	the olfactory mucosa	5152
@NP	olfactory function -LRB- Feron et al. , 1998 -RRB-	5192
@NP	olfactory function	5192
@NP	Feron	5212
@NP	et al. , 1998	5218
@NP	et al.	5218
@NP	1998	5226
@NP	A Phase I clinical trial	5233
@NP	A Phase I	5233
@NP	A Phase	5233
@NP	I	5241
@NP	clinical trial	5243
@NP	transplantation of autologous OECs	5276
@NP	transplantation	5276
@NP	autologous OECs	5295
@NP	human paraplegia -LRB- Feron et al. , 2005 ; Mackay-Sim et al. , 2008 -RRB-	5323
@NP	human paraplegia	5323
@NP	Feron	5341
@NP	et al. , 2005 ; Mackay-Sim et al. , 2008	5347
@NP	et al.	5347
@NP	2005 ; Mackay-Sim et al.	5355
@NP	2005	5355
@NP	Mackay-Sim et al.	5361
@NP	Mackay-Sim	5361
@NP	et al.	5372
@NP	2008	5380
@NP	The aim of this study	5387
@NP	The aim	5387
@NP	this study	5398
@NP	OECs	5434
@NP	the human mucosa	5453
@NP	green fluorescent protein	5500
@NP	similar behavioural outcomes	5546
@NP	that reported for rat OECs	5578
@NP	that	5578
@NP	rat OECs	5596
@NP	the remyelination potential of human bulbar OECs	5612
@NP	the remyelination potential	5612
@NP	human bulbar OECs	5643
@NP	this	5682
@NP	the first time	5690
@NP	locomotor improvements following human mucosal OEC transplants	5705
@NP	locomotor improvements	5705
@NP	human mucosal OEC transplants	5738
@NP	We	5792
@NP	the traumatic contusion model	5800
@NP	MASCIS impactor	5831
@NP	a complex central lesion with damage	5865
@NP	a complex central lesion	5865
@NP	damage	5895
@NP	spinal cord tissue and blood vessels	5905
@NP	ongoing secondary injury and cyst formation -LRB- Basso et al. , 1996 -RRB-	5947
@NP	ongoing secondary injury	5947
@NP	cyst formation -LRB- Basso et al. , 1996 -RRB-	5976
@NP	cyst formation	5976
@NP	Basso	5992
@NP	et al. , 1996	5998
@NP	et al.	5998
@NP	1996	6006
@NP	human spinal injury -LRB- Sekhon and Fehlings , 2001 -RRB-	6023
@NP	human spinal injury	6023
@NP	Sekhon and Fehlings	6044
@NP	2001	6065
@NP	The use of athymic rats -LRB- Rolstad , 2001 -RRB-	6072
@NP	The use	6072
@NP	athymic rats -LRB- Rolstad , 2001 -RRB-	6083
@NP	athymic rats	6083
@NP	Rolstad	6097
@NP	2001	6106
@NP	xenograft rejection of the hOECs	6119
@NP	xenograft rejection	6119
@NP	the hOECs	6142
@NP	transplantation	6166
@NP	a week	6188
@NP	injury	6201
@NP	exposure of the grafted cells to the acute inflammatory phase	6216
@NP	exposure	6216
@NP	the grafted cells to the acute inflammatory phase	6228
@NP	the grafted cells	6228
@NP	the acute inflammatory phase	6249
@NP	Results Fig. 1 -- Human OEC transplantation improved locomotor behaviour .	6283
@NP	Results Fig. 1	6283
@NP	Results	6283
@NP	Fig. 1	6291
@NP	Human OEC transplantation improved locomotor behaviour	6300
@NP	Human OEC transplantation	6300
@NP	locomotor behaviour	6335
@NP	-LRB- A -RRB- hOECs transplantation	6356
@NP	-LRB- A -RRB-	6356
@NP	hOECs transplantation	6360
@NP	triangles	6383
@NP	1 week after contusion injury	6397
@NP	1 week	6397
@NP	contusion injury	6410
@NP	locomotor recovery	6450
@NP	the BBB open field scores	6484
@NP	controls -LRB- circles -RRB-	6522
@NP	controls	6522
@NP	circles	6532
@NP	measures	6552
@NP	ANOVA , -LRB- F -LRB- 1,18 -RRB- = 9.6 , p = 0.006 -RRB-	6561
@NP	ANOVA	6561
@NP	F -LRB- 1,18 -RRB- = 9.6 , p	6569
@NP	F -LRB- 1,18 -RRB-	6569
@NP	F	6569
@NP	1,18	6572
@NP	9.6 , p	6578
@NP	9.6	6578
@NP	p	6583
@NP	0.006	6585
@NP	Bonferroni	6594
@NP	hoc tests show significant increases in the OEC group by 4 weeks post injury	6610
@NP	hoc	6610
@NP	tests	6614
@NP	significant increases in the OEC group	6625
@NP	significant increases	6625
@NP	the OEC group	6650
@NP	4 weeks post injury	6667
@NP	4 weeks	6667
@NP	-LRB- B -RRB- hOEC transplantation -LRB- dark bar -RRB-	6688
@NP	-LRB- B -RRB- hOEC transplantation	6688
@NP	-LRB- B -RRB-	6688
@NP	hOEC transplantation	6692
@NP	dark bar	6714
@NP	fewer stepping errors	6736
@NP	the controls -LRB- light bar -RRB- during the horizontal ladder task	6763
@NP	the controls -LRB- light bar -RRB-	6763
@NP	the controls	6763
@NP	light bar	6777
@NP	the horizontal ladder task	6795
@NP	p = 0.05	6824
@NP	p	6824
@NP	0.05	6826
@NP	Scores	6833
@NP	means and SEM	6849
@NP	Fig. 2 -- Human OEC transplantation and the lesion site .	6866
@NP	Fig. 2	6866
@NP	Human OEC transplantation and the lesion site	6875
@NP	Human OEC transplantation	6875
@NP	the lesion site	6905
@NP	-LRB- A , B -RRB- Horizontal sections	6922
@NP	A , B	6923
@NP	A	6923
@NP	B	6926
@NP	spinal cord	6952
@NP	H&E	6977
@NP	the lesion site	6989
@NP	5 weeks	7005
@NP	A	7020
@NP	control medium injection or -LRB- B -RRB- hOEC transplantation	7023
@NP	control medium injection	7023
@NP	B	7052
@NP	hOEC transplantation	7055
@NP	Large dotted box	7077
@NP	the total area	7100
@NP	the spinal cord	7128
@NP	Smaller dotted region	7160
@NP	Smaller	7160
@NP	region	7175
@NP	the lesion area	7188
@NP	cavities -LRB- * -RRB- and cell debris	7209
@NP	cavities -LRB- * -RRB-	7209
@NP	cavities	7209
@NP	cell debris	7226
@NP	-LRB- C -- E -RRB- High power images	7239
@NP	-LRB- C -- E -RRB- High power	7239
@NP	C -- E	7240
@NP	C	7240
@NP	E	7242
@NP	images	7256
@NP	the boxed areas in A and B.	7268
@NP	the	7268
@NP	areas	7278
@NP	A and B.	7287
@NP	A	7287
@NP	B.	7293
@NP	-LRB- C -RRB- The penumbra of the lesion	7296
@NP	The penumbra	7300
@NP	the lesion	7316
@NP	the peripheral white matter -LRB- wm -RRB-	7335
@NP	the peripheral white matter	7335
@NP	wm	7364
@NP	The centre	7373
@NP	the lesion	7387
@NP	the control animal containing cell debris , macrophages , and trabeculae	7401
@NP	the control animal	7401
@NP	cell debris , macrophages , and trabeculae	7431
@NP	cell debris	7431
@NP	macrophages	7444
@NP	trabeculae	7461
@NP	spinal tissue extending into the lesion -LRB- long arrows -RRB-	7475
@NP	spinal tissue	7475
@NP	the lesion -LRB- long arrows -RRB-	7504
@NP	the lesion	7504
@NP	long arrows	7516
@NP	-LRB- E -RRB- The centre of the lesion in the hOEC transplanted animal .	7530
@NP	-LRB- E -RRB- The centre of the lesion in the hOEC	7530
@NP	-LRB- E -RRB-	7530
@NP	The centre of the lesion in the hOEC	7534
@NP	The centre	7534
@NP	the lesion in the hOEC	7548
@NP	the lesion	7548
@NP	the hOEC	7562
@NP	animal	7584
@NP	Fig. 3	7593
@NP	hOECs	7615
@NP	lesion	7629
@NP	size , cavity area	7636
@NP	tissue sparing	7668
@NP	Measurements , expressed as percentages ,	7684
@NP	Measurements	7684
@NP	percentages	7711
@NP	the spinal cord	7741
@NP	the dorsal -LRB- left -RRB-	7762
@NP	the dorsal	7762
@NP	left	7774
@NP	the ventral -LRB- right -RRB- surface	7783
@NP	-LRB- A -RRB-	7812
@NP	Lesion area	7816
@NP	highest in the dorsal spinal cord and transplanted hOECs	7831
@NP	highest	7831
@NP	the dorsal spinal cord and transplanted hOECs	7842
@NP	the dorsal spinal cord	7842
@NP	transplanted hOECs	7869
@NP	lesion size	7896
@NP	-LRB- B -RRB-	7919
@NP	The cavity area within the lesion	7923
@NP	The cavity area	7923
@NP	the lesion	7946
@NP	the middle of the spinal cord	7972
@NP	the middle	7972
@NP	the spinal cord	7986
@NP	the hOEC	8017
@NP	transplanted animals compared to the controls	8026
@NP	transplanted animals	8026
@NP	the controls	8059
@NP	C	8074
@NP	Tissue sparing	8077
@NP	Tissue	8077
@NP	dorsal	8107
@NP	ventral cord	8117
@NP	both groups	8134
@NP	there	8155
@NP	differential sparing of tissue for the hOEC transplanted animals	8165
@NP	differential sparing	8165
@NP	tissue for the hOEC transplanted animals	8189
@NP	the hOEC	8200
@NP	hOEC transplants	8234
@NP	the GFAP intensity	8259
@NP	the lesion	8290
@NP	p < 0.05 .	8303
@NP	p	8303
@NP	< 0.05 .	8304
@NP	<	8304
@NP	0.05 .	8305
@NP	Fig. 4 -- Transplanted hOECs remained within the lesion .	8312
@NP	Fig. 4	8312
@NP	hOECs	8334
@NP	the lesion	8356
@NP	Horizontal sections of spinal cord 5 weeks after hOEC transplantation .	8368
@NP	Horizontal sections	8368
@NP	spinal cord 5 weeks	8391
@NP	spinal cord	8391
@NP	5 weeks	8403
@NP	hOEC transplantation	8417
@NP	-LRB- A -RRB- GFP labelled hOECs -LRB- green -RRB-	8439
@NP	-LRB- A -RRB-	8439
@NP	GFP	8443
@NP	hOECs	8456
@NP	the lesion	8489
@NP	the periphery of the lesion -LRB- dotted line -RRB-	8521
@NP	the periphery	8521
@NP	the lesion -LRB- dotted line -RRB-	8538
@NP	the lesion	8538
@NP	line	8557
@NP	Yellow cells -LRB- arrows -RRB-	8564
@NP	Yellow cells	8564
@NP	arrows	8578
@NP	autofluorescent macrophages	8590
@NP	similar numbers in hOEC	8626
@NP	similar numbers	8626
@NP	hOEC	8645
@NP	transplanted and control sections	8650
@NP	transplanted	8650
@NP	control sections	8667
@NP	-LRB- B -RRB- High power image of the GFP	8685
@NP	-LRB- B -RRB- High power image	8685
@NP	-LRB- B -RRB- High power	8685
@NP	B	8686
@NP	the GFP	8709
@NP	hOECs -LRB- green -RRB-	8726
@NP	hOECs	8726
@NP	their morphology and rostro-caudal orientation	8748
@NP	-LRB- C -RRB- Rarely , hOECs -LRB- open arrow -RRB-	8796
@NP	-LRB- C -RRB- Rarely	8796
@NP	-LRB- C -RRB-	8796
@NP	hOECs -LRB- open arrow -RRB-	8808
@NP	hOECs	8808
@NP	open arrow	8815
@NP	the parenchyma	8840
@NP	the lesion	8867
@NP	line	8886
@NP	lesion edge	8897
@NP	solid line	8910
@NP	spinal cord edge	8927
@NP	F	8952
@NP	images	8958
@NP	the same section	8968
@NP	-LRB- D -RRB- green filter only , -LRB- E -RRB- red filter only	8997
@NP	-LRB- D -RRB- green filter only	8997
@NP	-LRB- D -RRB- green filter	8997
@NP	D	8998
@NP	-LRB- E -RRB- red filter	9020
@NP	E	9021
@NP	F	9045
@NP	the autofluorescent cells -LRB- open arrows , yellow -RRB-	9070
@NP	the autofluorescent cells	9070
@NP	open arrows , yellow	9097
@NP	open arrows	9097
@NP	yellow	9110
@NP	the center	9121
@NP	the lesion	9135
@NP	hOEC -LRB- closed arrows , green -RRB-	9152
@NP	hOEC	9152
@NP	closed arrows , green	9158
@NP	closed arrows	9158
@NP	green	9173
@NP	These autofluorescent cells	9205
@NP	the control sections	9251
@NP	Fig. 5 -- Cellular interactions of transplanted hOECs .	9274
@NP	Fig. 5	9274
@NP	Cellular interactions of transplanted hOECs	9283
@NP	Cellular interactions	9283
@NP	transplanted hOECs	9308
@NP	Horizontal sections of spinal cord tissue 5 weeks after hOEC transplantation .	9328
@NP	Horizontal sections	9328
@NP	spinal cord tissue 5 weeks	9351
@NP	spinal cord tissue	9351
@NP	5 weeks	9370
@NP	hOEC transplantation	9384
@NP	-LRB- A -RRB- High levels of GFAP staining -LRB- red -RRB-	9406
@NP	-LRB- A -RRB- High levels of GFAP staining	9406
@NP	-LRB- A -RRB-	9406
@NP	High levels of GFAP staining	9410
@NP	High levels	9410
@NP	GFAP staining	9425
@NP	red	9440
@NP	the lesion -LRB- dotted line -RRB- in a control spinal cord	9469
@NP	the lesion -LRB- dotted line -RRB-	9469
@NP	the lesion	9469
@NP	line	9488
@NP	a control spinal cord	9497
@NP	-LRB- B -RRB-	9520
@NP	GFAP staining intensity	9532
@NP	the lesion in a hOECs transplanted spinal cord	9568
@NP	the lesion	9568
@NP	a hOECs transplanted spinal cord	9582
@NP	-LRB- C -RRB-	9616
@NP	the lesion	9623
@NP	interface hOECs -LRB- green , arrow -RRB-	9634
@NP	interface hOECs	9634
@NP	green , arrow	9651
@NP	green	9651
@NP	arrow	9658
@NP	astrocytic process -LRB- red , open arrowhead -RRB-	9669
@NP	astrocytic process	9669
@NP	red , open arrowhead	9689
@NP	red	9689
@NP	open arrowhead	9694
@NP	close proximity	9723
@NP	-LRB- D -RRB- NF-200 staining of axons in the peripheral white matter	9740
@NP	NF-200 staining	9744
@NP	axons in the peripheral white matter	9763
@NP	axons	9763
@NP	the peripheral white matter	9772
@NP	large axons	9808
@NP	apparent retraction balls -LRB- open arrow -RRB-	9825
@NP	apparent retraction balls	9825
@NP	open arrow	9852
@NP	terminal bulbs -LRB- closed arrow -RRB-	9868
@NP	terminal bulbs	9868
@NP	arrow	9891
@NP	-LRB- E -RRB- Confocal image	9899
@NP	-LRB- E -RRB-	9899
@NP	Confocal image	9903
@NP	hOECs	9926
@NP	green , arrows	9933
@NP	green	9933
@NP	arrows	9940
@NP	close association with NF200-positive axons -LRB- red , arrowheads -RRB-	9959
@NP	close association	9959
@NP	NF200-positive axons -LRB- red , arrowheads -RRB-	9982
@NP	NF200-positive axons	9982
@NP	red , arrowheads	10004
@NP	red	10004
@NP	arrowheads	10009
@NP	the periphery of the lesion	10024
@NP	the periphery	10024
@NP	the lesion	10041
@NP	-LRB- F -RRB- Longitudinal section of the spinal cord lesion from a hOEC	10053
@NP	-LRB- F -RRB- Longitudinal section	10053
@NP	F	10054
@NP	the spinal cord lesion from a hOEC	10081
@NP	the spinal cord lesion	10081
@NP	a hOEC	10109
@NP	transplanted rat immunoreacted with ED1 to identify macrophages/microglia	10116
@NP	transplanted rat	10116
@NP	ED1	10152
@NP	macrophages/microglia	10168
@NP	-LRB- G -RRB- High power	10191
@NP	G	10192
@NP	image	10206
@NP	F	10218
@NP	ED1-positive cells -LRB- red -RRB-	10229
@NP	ED1-positive cells	10229
@NP	autofluorescent cells -LRB- yellow -RRB-	10273
@NP	autofluorescent cells	10273
@NP	the lesion centre -LRB- open arrows -RRB-	10311
@NP	the lesion centre	10311
@NP	open arrows	10330
@NP	ED1-positive macrophages/microglia	10347
@NP	autofluorescence	10402
@NP	the white matter	10422
@NP	closed arrows	10440
@NP	2.1	10457
@NP	Twenty animals -LRB- 9 receiving hOECs and 11 controls -RRB-	10469
@NP	Twenty animals	10469
@NP	9 receiving hOECs and 11 controls	10485
@NP	9	10485
@NP	hOECs and 11 controls	10497
@NP	hOECs	10497
@NP	11 controls	10507
@NP	the final analysis	10533
@NP	Three animals	10553
@NP	the study	10586
@NP	the compression rate during spinal cord contusion and/or the initial BBB score	10604
@NP	the compression rate	10604
@NP	spinal cord contusion and/or the initial BBB score	10632
@NP	spinal cord contusion	10632
@NP	the initial BBB score	10661
@NP	more than two standard deviations from the group mean	10687
@NP	more than two standard deviations	10687
@NP	the group mean	10726
@NP	one animal	10745
@NP	post-operative complications	10776
@NP	The mean compression rate for the hOEC	10806
@NP	The mean compression rate	10806
@NP	the hOEC	10836
@NP	transplanted group	10845
@NP	0.36 ± 0.02 m/s compared to 0.38 ± 0.04 m/s for the control group	10868
@NP	0.36 ± 0.02 m/s	10868
@NP	0.38 ± 0.04 m/s for the control group	10895
@NP	0.38 ± 0.04 m/s	10895
@NP	the control group	10913
@NP	There	10932
@NP	no difference between the groups -LRB- t = 0.658 , df 18 , p = 0.52 -RRB-	10942
@NP	no difference	10942
@NP	the groups -LRB- t = 0.658 , df 18 , p = 0.52 -RRB-	10964
@NP	the groups	10964
@NP	t = 0.658 , df 18 , p = 0.52	10976
@NP	t = 0.658	10976
@NP	t	10976
@NP	0.658	10978
@NP	df 18	10985
@NP	df	10985
@NP	18	10988
@NP	p = 0.52	10992
@NP	p	10992
@NP	0.52	10994
@NP	The lesion locations	11001
@NP	the transplanted and non-transplanted group lesions	11042
@NP	The positioning of the impactor head between the T9 and T11 vertebrate	11095
@NP	The positioning	11095
@NP	the impactor head between the T9 and T11 vertebrate	11114
@NP	the impactor head	11114
@NP	the T9 and T11 vertebrate	11140
@NP	preventsmuch variation in lesion location between animals	11166
@NP	preventsmuch variation	11166
@NP	lesion location between animals	11192
@NP	lesion location	11192
@NP	animals	11216
@NP	There	11225
@NP	a small decrease in body weight -LRB- < 10 % -RRB- in the first week	11235
@NP	a small decrease	11235
@NP	body weight -LRB- < 10 % -RRB- in the first week	11255
@NP	body weight -LRB- < 10 % -RRB-	11255
@NP	body weight	11255
@NP	< 10 %	11268
@NP	<	11268
@NP	10 %	11269
@NP	the first week	11277
@NP	the surgery	11298
@NP	the 6-week post-contusion period	11337
@NP	baseline levels	11379
@NP	All rats	11396
@NP	urine	11432
@NP	2 weeks post-contusion surgery	11441
@NP	2 weeks	11441
@NP	The cell transplantation procedure 1 week after spinal cord contusion	11473
@NP	The cell transplantation procedure	11473
@NP	1 week	11508
@NP	spinal cord contusion	11521
@NP	any noticeable adverse effects	11557
@NP	obvious locomotor deficits	11597
@NP	all animals	11625
@NP	surgery	11674
@NP	2.2	11683
@NP	Phenotyping of cells	11688
@NP	Phenotyping	11688
@NP	cells	11703
@NP	transduction with pFB-hrGFP	11718
@NP	transduction	11718
@NP	pFB-hrGFP	11736
@NP	cells	11747
@NP	antibodies	11795
@NP	glial fibrillary acidic protein -LRB- GFAP ; Dako , Denmark -RRB-	11814
@NP	glial fibrillary acidic protein	11814
@NP	GFAP ; Dako , Denmark	11847
@NP	GFAP	11847
@NP	Dako , Denmark	11853
@NP	S100 -LRB- Dako , Denmark -RRB-	11869
@NP	S100	11869
@NP	Dako	11875
@NP	Denmark	11881
@NP	p75NTR -LRB- Neubody , AUS -RRB-	11891
@NP	p75NTR	11891
@NP	Neubody	11899
@NP	AUS	11908
@NP	R-phycoerythrin-conjugated anti- HNK1 -LRB- Sigma -RRB-	11917
@NP	R-phycoerythrin-conjugated anti- HNK1	11917
@NP	Sigma	11956
@NP	The percentages of S100-positive and GFAP positive cells	11964
@NP	The percentages	11964
@NP	S100-positive and GFAP positive cells	11983
@NP	GFAP	12001
@NP	95 % , nearly all cells	12027
@NP	95 %	12027
@NP	nearly all cells	12032
@NP	p75 NTR immunoreactive	12059
@NP	p75 NTR	12059
@NP	there	12086
@NP	no staining	12096
@NP	NHK	12111
@NP	1 antibody -LRB- Feron et al. , 2005 -RRB- indicating the culture	12115
@NP	1 antibody -LRB- Feron et al. , 2005 -RRB-	12115
@NP	Feron	12127
@NP	et al. , 2005	12133
@NP	et al.	12133
@NP	2005	12141
@NP	the culture	12158
@NP	OEC	12194
@NP	immunophenotyping of these cells	12207
@NP	immunophenotyping	12207
@NP	these cells	12228
@NP	transplantation	12254
@NP	no expression of any of these markers	12277
@NP	no expression	12277
@NP	any of these markers	12294
@NP	any	12294
@NP	these markers	12301
@NP	reasons	12320
@NP	Discussion	12341
@NP	we	12353
@NP	the most likely explanation	12365
@NP	this loss of expression	12397
@NP	this loss	12397
@NP	expression	12410
@NP	plasticity	12431
@NP	the OECs	12445
@NP	Barnett et al.	12493
@NP	Barnett	12493
@NP	et al.	12501
@NP	2000 ; Vincent et al.	12509
@NP	2000	12509
@NP	Vincent et al.	12515
@NP	Vincent	12515
@NP	et al.	12523
@NP	2003	12531
@NP	2005 ; Moreno-Flores et al. , 2003	12537
@NP	2005	12537
@NP	Moreno-Flores et al. , 2003	12543
@NP	Moreno-Flores	12543
@NP	et al. , 2003	12557
@NP	et al.	12557
@NP	2003	12565
@NP	replacement of all the OECs by another immunonegative cell type	12584
@NP	replacement	12584
@NP	all the OECs by another immunonegative cell type	12599
@NP	all the OECs	12599
@NP	another immunonegative cell type	12615
@NP	We	12649
@NP	the term hOECs	12672
@NP	these transplants	12699
@NP	their identity	12734
@NP	2.3	12765
@NP	Behavioural assessments 2.3.1 .	12770
@NP	Behavioural assessments	12770
@NP	2.3.1	12794
@NP	field assessment	12806
@NP	the 6 weeks following hOEC transplantation or medium injection	12830
@NP	the 6 weeks	12830
@NP	hOEC transplantation or medium injection	12852
@NP	hOEC transplantation	12852
@NP	medium injection	12876
@NP	there	12893
@NP	an increase	12903
@NP	BBB scores	12918
@NP	both groups -LRB- Fig. 1A -RRB-	12933
@NP	both groups	12933
@NP	Fig. 1A	12946
@NP	a significantly greater improvement in the hOEC transplant group	12960
@NP	a significantly greater improvement	12960
@NP	the hOEC transplant group	12999
@NP	two way ANOVA repeated measures , F -LRB- 1,18 -RRB- = 9.6 , p = 0.006	13027
@NP	two way	13027
@NP	ANOVA	13035
@NP	measures , F -LRB- 1,18 -RRB- = 9.6 ,	13050
@NP	measures	13050
@NP	F -LRB- 1,18 -RRB- = 9.6	13060
@NP	F -LRB- 1,18 -RRB-	13060
@NP	F	13060
@NP	1,18	13063
@NP	9.6	13069
@NP	p = 0.006	13074
@NP	p	13074
@NP	0.006	13076
@NP	Bonferroni	13084
@NP	hoc tests show significant increases in the OEC group by 4 weeks post injury	13100
@NP	hoc	13100
@NP	tests	13104
@NP	significant increases in the OEC group	13115
@NP	significant increases	13115
@NP	the OEC group	13140
@NP	4 weeks post injury	13157
@NP	4 weeks	13157
@NP	The BBB scores	13178
@NP	the hOEC transplanted animals at 6 weeks	13205
@NP	the hOEC transplanted animals	13205
@NP	6 weeks	13238
@NP	15.8 ± 2.9	13247
@NP	15.8 ±	13247
@NP	2.9	13252
@NP	better hind-fore limb coordination , paw placement and trunk stability	13266
@NP	better hind-fore limb coordination	13266
@NP	paw placement	13302
@NP	trunk stability	13320
@NP	the controls -LRB- 12.45 ± 2.0 -RRB-	13348
@NP	the controls	13348
@NP	12.45 ± 2.0	13362
@NP	12.45	13362
@NP	± 2.0	13367
@NP	2.3.2	13374
@NP	Horizontal Ladder	13381
@NP	test	13412
@NP	Six weeks	13417
@NP	transplantation	13433
@NP	most animals	13449
@NP	withweight support andmostwere	13484
@NP	the horizontal ladder	13535
@NP	the animals	13569
@NP	this task	13601
@NP	the hindlimb deficits	13615
@NP	the open field test	13670
@NP	Each animal	13691
@NP	variability	13710
@NP	the task	13736
@NP	spasms or jumps	13766
@NP	movement	13785
@NP	a stepping error	13812
@NP	Only consecutive steps completed after the rat	13830
@NP	Only consecutive steps	13830
@NP	the rat	13869
@NP	itself	13892
@NP	The hOEC-treated group	13912
@NP	significantly fewer stepping errors	13940
@NP	this task -LRB- 34.2 ± 20 % -RRB-	13979
@NP	this task	13979
@NP	34.2 ± 20 %	13990
@NP	34.2 ±	13990
@NP	20 %	13995
@NP	the control group -LRB- 50.8 ± 15.5 % -RRB-	14005
@NP	the control group	14005
@NP	50.8 ± 15.5 %	14024
@NP	50.8 ±	14024
@NP	15.5 %	14029
@NP	t = 2.12 , df 15 , p = 0.05	14038
@NP	t = 2.12	14038
@NP	t	14038
@NP	= 2.12	14039
@NP	df 15	14046
@NP	df	14046
@NP	15	14049
@NP	p = 0.05	14053
@NP	p	14053
@NP	0.05	14055
@NP	Fig. 1B	14062
@NP	2.4	14072
@NP	Histological analysis 2.4.1 .	14077
@NP	Histological analysis	14077
@NP	2.4.1	14099
@NP	Lesion size This moderate contusion	14106
@NP	Lesion size	14106
@NP	This moderate contusion	14118
@NP	a typical `` oval '' shaped injury	14154
@NP	a large centrally located lesion	14190
@NP	necrotic tissue	14234
@NP	cellular debris	14251
@NP	macrophages	14268
@NP	cystic cavities	14281
@NP	trabeculae of tissue	14301
@NP	trabeculae	14301
@NP	tissue	14315
@NP	Fig. 2A -- E	14323
@NP	Fig. 2A	14323
@NP	E	14331
@NP	the lesion	14347
@NP	there	14358
@NP	relative sparing of tissue	14368
@NP	relative sparing	14368
@NP	tissue	14388
@NP	extensive diffuse axonal injury in the white matter	14399
@NP	extensive diffuse axonal injury	14399
@NP	the white matter	14434
@NP	The terminal bulbs of axons	14452
@NP	The terminal bulbs	14452
@NP	axons	14474
@NP	their smooth rounded appearance	14501
@NP	eosinophilic staining in H&E	14537
@NP	eosinophilic staining	14537
@NP	H&E	14562
@NP	sections -LRB- Fig. 2C -RRB-	14574
@NP	sections	14574
@NP	Fig. 2C	14584
@NP	the peripheral white matter with NF-200 staining -LRB- Fig. 5D -RRB-	14625
@NP	the peripheral white matter	14625
@NP	NF-200 staining -LRB- Fig. 5D -RRB-	14658
@NP	NF-200 staining	14658
@NP	Fig. 5D	14675
@NP	Spinal cords with hOEC transplants	14685
@NP	Spinal cords	14685
@NP	hOEC transplants	14703
@NP	smaller lesions with less cavitation -LRB- Fig. 2B , E -RRB-	14724
@NP	smaller lesions	14724
@NP	less cavitation -LRB- Fig. 2B , E -RRB-	14745
@NP	less cavitation	14745
@NP	Fig. 2B , E	14762
@NP	Fig. 2B	14762
@NP	E	14771
@NP	The overall percentage of lesion area	14775
@NP	The overall percentage	14775
@NP	lesion area	14801
@NP	the hOEC	14840
@NP	spinal cords -LRB- 37.2 ± 6.6 % -RRB-	14862
@NP	spinal cords	14862
@NP	37.2 ± 6.6 %	14876
@NP	37.2 ±	14876
@NP	6.6 %	14881
@NP	the controls -LRB- 51.04 ± 5.4 % -RRB- , -LRB- t = 5.1 , df 18 , p < 0.001 -RRB-	14899
@NP	the controls -LRB- 51.04 ± 5.4 % -RRB- ,	14899
@NP	the controls	14899
@NP	51.04 ± 5.4 %	14913
@NP	51.04	14913
@NP	± 5.4 %	14918
@NP	t = 5.1 , df 18 , p < 0.001	14927
@NP	t = 5.1	14927
@NP	t	14927
@NP	df 18	14934
@NP	df	14934
@NP	18	14937
@NP	p < 0.001	14941
@NP	p <	14941
@NP	p	14941
@NP	0.001	14943
@NP	The dorsal part of the cord	14951
@NP	The dorsal part	14951
@NP	the cord	14970
@NP	the most injury	14989
@NP	there	15009
@NP	no difference	15019
@NP	severity for hOEC transplanted animals and controls at this level	15036
@NP	severity for hOEC transplanted animals	15036
@NP	severity	15036
@NP	hOEC transplanted animals	15049
@NP	controls at this level	15079
@NP	controls	15079
@NP	this level	15091
@NP	each of the middle levels through the cord the hOEC	15106
@NP	each	15106
@NP	the middle levels through the cord the hOEC	15114
@NP	the middle levels	15114
@NP	the cord the hOEC	15140
@NP	the cord	15140
@NP	the hOEC	15149
@NP	transplanted animals	15158
@NP	consistently smaller lesion sizes -LRB- Fig. 3A -RRB-	15186
@NP	consistently smaller lesion sizes	15186
@NP	Fig. 3A	15221
@NP	the lesion	15238
@NP	the overall percentage of cavity area	15250
@NP	the overall percentage	15250
@NP	cavity area	15276
@NP	hOEC groups -LRB- 3.1 ± 2.7 % -RRB-	15318
@NP	hOEC groups	15318
@NP	3.1 ± 2.7 %	15331
@NP	3.1 ±	15331
@NP	2.7 %	15336
@NP	the controls -LRB- 15.5 ± 15.3 % -RRB- , -LRB- t = 2.2 , df 18 , p = 0.038 -RRB-	15354
@NP	the controls -LRB- 15.5 ± 15.3 % -RRB- ,	15354
@NP	the controls	15354
@NP	15.5 ± 15.3 %	15368
@NP	15.5	15368
@NP	± 15.3 %	15372
@NP	t = 2.2 , df 18 , p = 0.038	15382
@NP	t = 2.2	15382
@NP	t	15382
@NP	2.2	15384
@NP	df 18	15389
@NP	df	15389
@NP	18	15392
@NP	p = 0.038	15396
@NP	p	15396
@NP	0.038	15398
@NP	Cavitation	15406
@NP	highest in the middle sections of the spinal cord for both groups	15421
@NP	highest	15421
@NP	the middle sections of the spinal cord for both groups	15432
@NP	the middle sections	15432
@NP	the spinal cord for both groups	15455
@NP	the spinal cord	15455
@NP	both groups	15475
@NP	the controls	15493
@NP	significantly greater cavitation	15514
@NP	hOEC transplanted animals at the central level -LRB- Fig. 3B -RRB-	15552
@NP	hOEC transplanted animals	15552
@NP	the central level -LRB- Fig. 3B -RRB-	15581
@NP	the central level	15581
@NP	Fig. 3B	15600
@NP	a few individual cells -LRB- Fig. 4C -RRB-	16267
@NP	a few individual cells	16267
@NP	Fig. 4C	16291
@NP	hOECs	16300
@NP	the lesion	16327
@NP	spinal cord tissue	16355
@NP	2.4.3	16375
@NP	Immunohistochemistry Six weeks after transplantation , GFAP staining intensity	16382
@NP	Immunohistochemistry	16382
@NP	Six weeks	16403
@NP	transplantation , GFAP staining intensity	16419
@NP	transplantation	16419
@NP	GFAP staining intensity	16436
@NP	the lesion in controls -LRB- Fig. 5A -RRB-	16498
@NP	the lesion	16498
@NP	controls -LRB- Fig. 5A -RRB-	16512
@NP	controls	16512
@NP	Fig. 5A	16522
@NP	a lesser extent in hOEC	16538
@NP	a lesser extent	16538
@NP	hOEC	16557
@NP	transplanted spinal cords -LRB- Fig. 5B -RRB-	16562
@NP	transplanted spinal cords	16562
@NP	Fig. 5B	16589
@NP	Quantification of the GFAP staining intensity	16599
@NP	Quantification	16599
@NP	the GFAP staining intensity	16617
@NP	an overall 17 % reduction	16652
@NP	GFAP intensity in hOEC transplanted rats	16680
@NP	GFAP intensity	16680
@NP	hOEC transplanted rats	16698
@NP	The control animals	16722
@NP	a 27 ± 9.5 % increase in GFAP staining intensity	16749
@NP	a 27 ± 9.5 % increase	16749
@NP	9.5 %	16754
@NP	GFAP staining intensity	16771
@NP	the lesion	16807
@NP	an increase	16830
@NP	10 ± 6.6 % in the hOEC transplanted animals	16845
@NP	the hOEC	16857
@NP	t = 4.5 , df 18 , p = 0.001	16888
@NP	t = 4.5	16888
@NP	t	16888
@NP	4.5	16890
@NP	df 18	16895
@NP	df	16895
@NP	18	16898
@NP	p = 0.001	16902
@NP	p	16902
@NP	0.001	16904
@NP	This pattern	16912
@NP	the spinal cord	16951
@NP	the ventral section	16980
@NP	significant differences -LRB- Fig. 3D -RRB-	17007
@NP	significant differences	17007
@NP	Fig. 3D	17032
@NP	High power examination at the edge of the lesion	17042
@NP	High power examination	17042
@NP	the edge of the lesion	17068
@NP	the edge	17068
@NP	the lesion	17080
@NP	close association	17098
@NP	some hOECs and GFAP positive astrocytes	17124
@NP	some hOECs	17124
@NP	GFAP positive astrocytes	17139
@NP	the host-graft interface -LRB- Fig. 5C -RRB-	17167
@NP	the host-graft interface	17167
@NP	Fig. 5C	17193
@NP	Occasional single hOECs	17203
@NP	short distances	17247
@NP	the white matter	17271
@NP	astrocytic processes	17293
@NP	the centre of the lesion	17342
@NP	the centre	17342
@NP	the lesion	17356
@NP	GFAP staining	17368
@NP	trabeculae of tissue fragments	17399
@NP	trabeculae	17399
@NP	tissue fragments	17413
@NP	the lesion centre	17437
@NP	NF200 staining	17456
@NP	large axons and terminal bulbs	17482
@NP	large axons	17482
@NP	the white matter adjacent to the lesion -LRB- Fig. 5D -RRB-	17516
@NP	the white matter	17516
@NP	the lesion -LRB- Fig. 5D -RRB-	17545
@NP	the lesion	17545
@NP	Fig. 5D	17557
@NP	hOECs	17567
@NP	close proximity	17589
@NP	axons at the caudal and rostral ends of the lesion	17608
@NP	axons	17608
@NP	the caudal and rostral ends of the lesion	17617
@NP	the caudal and rostral ends	17617
@NP	the lesion	17648
@NP	few of these axons	17663
@NP	few	17663
@NP	these axons	17670
@NP	the epicentre	17697
@NP	The hOECs	17712
@NP	the same direction as axons	17748
@NP	the same direction	17748
@NP	axons	17770
@NP	confocal examination	17780
@NP	a close association	17811
@NP	some hOECs and NF200-positive axons -LRB- Fig. 5E -RRB-	17839
@NP	some hOECs and NF200-positive axons	17839
@NP	hOECs	17844
@NP	Fig. 5E	17876
@NP	it	17889
@NP	hOECs	17925
@NP	axons	17947
@NP	High numbers of large autofluorescent cells with macrophage morphology	17954
@NP	High numbers	17954
@NP	large autofluorescent cells with macrophage morphology	17970
@NP	large autofluorescent cells	17970
@NP	macrophage morphology	18003
@NP	the lesion centre of hOEC	18041
@NP	the lesion centre	18041
@NP	hOEC	18062
@NP	transplanted -LRB- Fig. 4A , D -- F -RRB- and control spinal cords	18067
@NP	transplanted -LRB- Fig. 4A , D -- F -RRB- and control	18067
@NP	transplanted -LRB- Fig. 4A , D -- F -RRB-	18067
@NP	transplanted	18067
@NP	Fig. 4A , D -- F	18081
@NP	Fig. 4A	18081
@NP	D -- F	18090
@NP	D	18090
@NP	F	18092
@NP	control	18099
@NP	spinal cords	18107
@NP	ED1	18135
@NP	a specific marker for rat myeloid cells	18140
@NP	a specific marker	18140
@NP	rat myeloid cells	18162
@NP	these	18191
@NP	macrophages or microglia -LRB- Fig. 5F , G -RRB-	18202
@NP	macrophages or microglia	18202
@NP	Fig. 5F , G	18228
@NP	Fig. 5F	18228
@NP	G	18237
@NP	there	18257
@NP	an extensive infiltration	18272
@NP	ED1-positive cells in the white matter throughout the spinal cord segment	18301
@NP	ED1-positive cells	18301
@NP	the white matter throughout the spinal cord segment	18323
@NP	the white matter	18323
@NP	the spinal cord segment	18351
@NP	There	18376
@NP	no apparent difference	18386
@NP	the amount or pattern	18412
@NP	macrophage staining between hOEC transplanted and control spinal cords	18437
@NP	macrophage staining	18437
@NP	hOEC transplanted and control spinal cords	18465
@NP	hOEC	18465
@NP	transplanted and control spinal cords	18470
@NP	transplanted	18470
@NP	control spinal cords	18487
@NP	Discussion	18513
@NP	this study	18527
@NP	we	18538
@NP	hOEC-derived cells from the olfactory mucosa	18551
@NP	hOEC-derived cells	18551
@NP	the olfactory mucosa	18575
@NP	significant locomotor and histological improvements	18604
@NP	transplantation	18662
@NP	the contused spinal cord of the rat	18683
@NP	the	18683
@NP	spinal cord of the rat	18696
@NP	spinal cord	18696
@NP	the rat	18711
@NP	controls	18732
@NP	the hOEC	18741
@NP	transplanted animals	18750
@NP	better hindlimb locomotor function	18789
@NP	the open field test , fewer stepping errors in the horizontal ladder task ,	18827
@NP	the open field test	18827
@NP	fewer stepping errors in the horizontal ladder task	18848
@NP	fewer stepping errors	18848
@NP	the horizontal ladder task	18873
@NP	spinal cord	18909
@NP	lesion volume	18921
@NP	cavitation	18947
@NP	the lesion	18965
@NP	There	18977
@NP	evidence for reduced astrogliosis at the lesion site	18992
@NP	evidence	18992
@NP	reduced astrogliosis at the lesion site	19005
@NP	reduced astrogliosis	19005
@NP	the lesion site	19029
@NP	3.1	19046
@NP	Human OECs from olfactory mucosa The cells used in this study	19051
@NP	Human OECs	19051
@NP	olfactory mucosa The cells used in this study	19067
@NP	olfactory mucosa	19067
@NP	The cells	19084
@NP	this study	19102
@NP	the human olfactory mucosa	19130
@NP	OEC cultures from this source	19158
@NP	OEC cultures	19158
@NP	this source	19176
@NP	Schwann cells	19220
@NP	the trigeminal nerve	19250
@NP	branches	19277
@NP	olfactory epithelium and olfactory bulb -LRB- Schaefer et al. , 2002 -RRB-	19296
@NP	olfactory epithelium and olfactory bulb	19296
@NP	Schaefer	19337
@NP	et al. , 2002	19346
@NP	et al.	19346
@NP	2002	19354
@NP	other cell types located in the olfactory mucosa	19364
@NP	other cell types	19364
@NP	the olfactory mucosa	19392
@NP	precursor cells and stem cells	19424
@NP	precursor cells	19424
@NP	stem cells	19444
@NP	Lindsay	19456
@NP	et al. , 2010	19464
@NP	et al.	19464
@NP	2010	19472
@NP	A comprehensive review article by Kawaja et al. -LRB- 2009 -RRB-	19479
@NP	A comprehensive review article by Kawaja et al.	19479
@NP	A comprehensive review article by Kawaja	19479
@NP	A comprehensive review article	19479
@NP	Kawaja	19513
@NP	et al.	19520
@NP	2009	19528
@NP	the technical challenges	19544
@NP	OECs	19609
@NP	olfactory bulb and mucosal tissue cultures	19619
@NP	Several antigenic markers , including calponin and smooth muscle actin ,	19663
@NP	Several antigenic markers	19663
@NP	calponin and smooth muscle actin	19700
@NP	calponin	19700
@NP	muscle actin	19720
@NP	OECs but not Schwann cells -LRB- Boyd et al. , 2006 ; Jahed et al. , 2007 -RRB-	19765
@NP	OECs	19765
@NP	Schwann cells -LRB- Boyd et al. , 2006 ; Jahed et al. , 2007 -RRB-	19778
@NP	Schwann cells	19778
@NP	Boyd	19793
@NP	et al. , 2006 ; Jahed et al. , 2007	19798
@NP	et al.	19798
@NP	2006 ; Jahed et al.	19806
@NP	2006	19806
@NP	Jahed et al.	19812
@NP	Jahed	19812
@NP	et al.	19818
@NP	2007	19826
@NP	these	19836
@NP	there	19894
@NP	no method to unequivocally distinguish between OECs and Schwann cells in vitro	19903
@NP	OECs and Schwann cells	19950
@NP	We	19983
@NP	a serum-free medium	19991
@NP	NT3	20022
@NP	OECs -LRB- Bianco et al. , 2004 -RRB-	20051
@NP	OECs	20051
@NP	Bianco	20057
@NP	et al. , 2004	20064
@NP	et al.	20064
@NP	2004	20072
@NP	This medium	20079
@NP	long-term culture of Schwann cells -LRB- Cheng et al. , 1998 -RRB-	20108
@NP	long-term culture	20108
@NP	Schwann cells -LRB- Cheng et al. , 1998 -RRB-	20129
@NP	Schwann cells	20129
@NP	Cheng	20144
@NP	et al. , 1998	20150
@NP	et al.	20150
@NP	1998	20158
@NP	NT3	20173
@NP	survival of 50 % Schwann cells	20186
@NP	survival	20186
@NP	50 % Schwann cells	20198
@NP	the first 3 h of culture -LRB- Meier et al. , 1999 -RRB-	20219
@NP	the first 3 h	20219
@NP	culture -LRB- Meier et al. , 1999 -RRB-	20236
@NP	culture	20236
@NP	Meier	20245
@NP	et al. , 1999	20251
@NP	et al.	20251
@NP	1999	20259
@NP	20-30 % in the first 24 h -LRB- Lobsiger et al. , 2000 -RRB-	20269
@NP	20-30 %	20269
@NP	the first 24 h -LRB- Lobsiger et al. , 2000 -RRB-	20279
@NP	the first 24 h	20279
@NP	Lobsiger	20295
@NP	et al. , 2000	20304
@NP	et al.	20304
@NP	2000	20312
@NP	no cells	20332
@NP	HNK 1	20362
@NP	a marker	20369
@NP	human myelinating Schwann cells -LRB- Levi et al. , 1994 -RRB-	20394
@NP	human myelinating Schwann cells	20394
@NP	Levi	20427
@NP	et al. , 1994	20432
@NP	et al.	20432
@NP	1994	20440
@NP	our paper	20458
@NP	we	20468
@NP	the transplanted cells as hOECs	20488
@NP	the transplanted cells	20488
@NP	hOECs	20514
@NP	we	20530
@NP	these cell preparations	20542
@NP	OECs	20592
@NP	it	20597
@NP	the transplants	20617
@NP	other , as yet unidentified , cell types from the olfactory mucosa	20641
@NP	other , as yet unidentified , cell types	20641
@NP	the olfactory mucosa	20685
@NP	The loss	20707
@NP	expression of GFAP , S100 and P75	20719
@NP	expression	20719
@NP	GFAP , S100 and P75	20733
@NP	these cells during their preparation	20755
@NP	these cells	20755
@NP	their preparation	20774
@NP	EGFP labelling , frozen storage and subsequent revival and expansion	20793
@NP	EGFP labelling	20793
@NP	frozen storage	20809
@NP	subsequent revival and expansion	20828
@NP	a matter of concern	20865
@NP	a matter	20865
@NP	concern	20877
@NP	one	20889
@NP	phenotyping cells	20930
@NP	each step of their preparation	20951
@NP	each step	20951
@NP	their preparation	20964
@NP	a more comprehensive panel	20988
@NP	antibodies -LRB- Lim et al. , 2010 ; Garcia-Escudero , et al. , 2010 -RRB-	21018
@NP	antibodies	21018
@NP	Lim	21030
@NP	et al. , 2010 ; Garcia-Escudero , et al. , 2010	21034
@NP	et al.	21034
@NP	2010 ; Garcia-Escudero , et al.	21042
@NP	2010	21042
@NP	Garcia-Escudero , et al.	21048
@NP	Garcia-Escudero	21048
@NP	et al.	21065
@NP	2010	21073
@NP	hOECs	21092
@NP	the same NT3 culture conditions	21110
@NP	the subsequent labelling and storage	21155
@NP	steps	21192
@NP	their GFAP	21209
@NP	+	21219
@NP	S100	21222
@NP	+	21226
@NP	p75-NGF + phenotype -LRB- Feron et al. , 2005 -RRB-	21229
@NP	p75-NGF + phenotype	21229
@NP	p75-NGF	21229
@NP	phenotype	21237
@NP	Feron	21248
@NP	et al. , 2005	21254
@NP	et al.	21254
@NP	2005	21262
@NP	OECs	21269
@NP	the expression of markers	21304
@NP	the expression	21304
@NP	markers	21322
@NP	culture conditions	21342
@NP	Barnett et al. , 2000 ; Vincent et al. , 2003 , 2005	21362
@NP	Barnett et al.	21362
@NP	Barnett	21362
@NP	et al.	21370
@NP	2000 ; Vincent et al.	21378
@NP	2000	21378
@NP	Vincent et al.	21384
@NP	Vincent	21384
@NP	et al.	21392
@NP	2003 , 2005	21400
@NP	2003	21400
@NP	2005	21406
@NP	species	21416
@NP	Bock	21425
@NP	et al. , 2007 ; Smithson and Kawaja , 2009	21430
@NP	et al.	21430
@NP	2007 ; Smithson and Kawaja	21438
@NP	2007	21438
@NP	Smithson and Kawaja	21444
@NP	2009	21465
@NP	p75-NGF	21472
@NP	incubation in 10 % fetal calf serum	21505
@NP	incubation	21505
@NP	10 % fetal calf serum	21519
@NP	loss of regenerative capacity -LRB- Moreno-Flores et al. , 2003 -RRB-	21548
@NP	loss	21548
@NP	regenerative capacity	21556
@NP	Moreno-Flores	21579
@NP	et al. , 2003	21593
@NP	et al.	21593
@NP	2003	21601
@NP	It	21608
@NP	the hOECs	21628
@NP	their immunological phenotype	21648
@NP	the particular protocol we used	21685
@NP	the particular protocol	21685
@NP	we	21709
@NP	The less likely possibility	21718
@NP	OECs -LRB- and Schwann cells -RRB-	21763
@NP	OECs	21763
@NP	Schwann cells	21773
@NP	the cell culture	21815
@NP	transplantation	21853
@NP	it	21874
@NP	a different cell population	21900
@NP	A recent review -LRB- Lindsay et al. , 2010 -RRB-	21929
@NP	A recent review	21929
@NP	Lindsay	21946
@NP	et al. , 2010	21954
@NP	et al.	21954
@NP	2010	21962
@NP	the complexity and heterogenicity of cells located in the human olfactory mucosa	21977
@NP	the complexity and heterogenicity	21977
@NP	cells located in the human olfactory mucosa	22014
@NP	cells	22014
@NP	the human olfactory mucosa	22031
@NP	this	22062
@NP	the case	22070
@NP	it	22084
@NP	these cells	22111
@NP	we	22126
@NP	their potential	22147
@NP	function	22177
@NP	spinal cord injury	22192
@NP	Clinical application of OECs	22212
@NP	Clinical application	22212
@NP	OECs	22236
@NP	an accessible source of these cells	22250
@NP	an accessible source	22250
@NP	these cells	22274
@NP	the majority of experiments	22290
@NP	the majority	22290
@NP	experiments	22306
@NP	OECs	22318
@NP	the rodent olfactory bulb	22342
@NP	amethod	22372
@NP	unilateral bulbectomy	22401
@NP	the frontal bone in primate -LRB- Rubio et al. , 2008 -RRB-	22431
@NP	the frontal bone	22431
@NP	primate -LRB- Rubio et al. , 2008 -RRB-	22451
@NP	primate	22451
@NP	Rubio	22460
@NP	et al. , 2008	22466
@NP	et al.	22466
@NP	2008	22474
@NP	OECs	22481
@NP	postmortem brain -LRB- Barnett et al. , 2000 -RRB-	22510
@NP	postmortem brain	22510
@NP	Barnett	22528
@NP	et al. , 2000	22536
@NP	et al.	22536
@NP	2000	22544
@NP	a clinically preferable source	22554
@NP	the olfactory mucosa	22588
@NP	the external naris	22629
@NP	Feron	22649
@NP	et al. , 1998 ; Bianco et al. , 2004	22655
@NP	et al.	22655
@NP	1998 ; Bianco et al.	22663
@NP	1998	22663
@NP	Bianco et al.	22669
@NP	Bianco	22669
@NP	et al.	22676
@NP	2004	22684
@NP	there	22698
@NP	little morbidity	22707
@NP	it	22728
@NP	autologous transplantation	22738
@NP	Feron	22766
@NP	et al. , 2005 ; Mackay-Sim et al. , 2008	22772
@NP	et al.	22772
@NP	2005 ; Mackay-Sim et al.	22780
@NP	2005	22780
@NP	Mackay-Sim et al.	22786
@NP	Mackay-Sim	22786
@NP	et al.	22797
@NP	2008	22805
@NP	This	22812
@NP	the first study	22820
@NP	hOECs	22845
@NP	the contusion model of spinal cord injury	22874
@NP	the contusion model	22874
@NP	spinal cord injury	22897
@NP	the results	22920
@NP	more marked post-transplantation improvements in hindlimb locomotion	22937
@NP	more marked post-transplantation improvements	22937
@NP	hindlimb locomotion	22986
@NP	rodent OEC transplantation	23018
@NP	similar models	23048
@NP	Barakat et al. , 2005 ; Pearse et al. , 2004 ; Takami et al. , 2002	23064
@NP	Barakat	23064
@NP	et al. , 2005 ; Pearse et al. , 2004 ; Takami et al. , 2002	23072
@NP	et al. , 2005	23072
@NP	et al.	23072
@NP	2005	23080
@NP	Pearse et al. , 2004	23086
@NP	Pearse	23086
@NP	et al. , 2004	23093
@NP	et al.	23093
@NP	2004	23101
@NP	Takami et al. , 2002	23107
@NP	Takami	23107
@NP	et al. , 2002	23114
@NP	et al.	23114
@NP	2002	23122
@NP	This	23129
@NP	the possibility	23141
@NP	hOECs	23162
@NP	rodent OECs	23197
@NP	recent	23225
@NP	studies	23241
@NP	rodent , canine , primate and human OECs	23252
@NP	interspecies differences in proliferation	23302
@NP	interspecies differences	23302
@NP	proliferation	23330
@NP	responses	23348
@NP	growth factors	23361
@NP	Barnett et al. , 2000 ; Krudewig et al. , 2006 ; Rubio et al. , 2008	23377
@NP	Barnett	23377
@NP	et al. , 2000 ; Krudewig et al. , 2006 ; Rubio et al. , 2008	23385
@NP	et al. , 2000	23385
@NP	et al.	23385
@NP	2000	23393
@NP	Krudewig et al. , 2006	23399
@NP	Krudewig	23399
@NP	et al. , 2006	23408
@NP	et al.	23408
@NP	2006	23416
@NP	Rubio et al. , 2008	23422
@NP	Rubio	23422
@NP	et al. , 2008	23428
@NP	et al.	23428
@NP	2008	23436
@NP	Another source of variation between studies	23443
@NP	Another source	23443
@NP	variation between studies	23461
@NP	variation	23461
@NP	studies	23479
@NP	the different methods of cell culture used in different laboratories	23496
@NP	the different methods	23496
@NP	cell culture used in different laboratories	23521
@NP	cell culture	23521
@NP	different laboratories	23542
@NP	There	23566
@NP	variability	23575
@NP	the reported survival of OECs after transplantation into the spinal cord	23590
@NP	the reported survival	23590
@NP	OECs after transplantation into the spinal cord	23615
@NP	OECs	23615
@NP	transplantation into the spinal cord	23626
@NP	transplantation	23626
@NP	the spinal cord	23647
@NP	The use of genetic reporter GFP	23664
@NP	The use	23664
@NP	genetic reporter GFP	23675
@NP	unequivocal visualisation	23705
@NP	transplantation	23737
@NP	Guest et al. , 2008 ; Pearse et al. , 2007 ; Sasaki et al. , 2007	23754
@NP	Guest	23754
@NP	et al. , 2008 ; Pearse et al. , 2007 ; Sasaki et al. , 2007	23760
@NP	et al. , 2008	23760
@NP	et al.	23760
@NP	2008	23768
@NP	Pearse et al. , 2007	23774
@NP	Pearse	23774
@NP	et al. , 2007	23781
@NP	et al.	23781
@NP	2007	23789
@NP	Sasaki et al. , 2007	23795
@NP	Sasaki	23795
@NP	et al. , 2007	23802
@NP	et al.	23802
@NP	2007	23810
@NP	hOECs	23820
@NP	6 weeks	23839
@NP	our study	23850
@NP	The timing of hOEC transplantation in this study	23861
@NP	The timing	23861
@NP	hOEC transplantation in this study	23875
@NP	hOEC transplantation	23875
@NP	this study	23899
@NP	7 days	23928
@NP	contusion injury	23941
@NP	this	23966
@NP	transplantation	24015
@NP	the time of injury	24034
@NP	the time	24034
@NP	injury	24046
@NP	Plant et al. , 2003	24054
@NP	Plant	24054
@NP	et al.	24060
@NP	2003	24068
@NP	The toxicity of the lesion site to transplanted OECs	24075
@NP	The toxicity	24075
@NP	the lesion site to transplanted OECs	24091
@NP	the lesion site	24091
@NP	transplanted OECs	24110
@NP	differences in the survival rate	24148
@NP	differences	24148
@NP	the survival rate	24163
@NP	69 % at 3 days to less than 5 % by 3	24182
@NP	69 %	24182
@NP	3 days to less than 5 % by 3	24189
@NP	3 days	24189
@NP	less than 5 % by 3	24199
@NP	less than 5 %	24199
@NP	3	24215
@NP	9 weeks after transplantation	24217
@NP	9 weeks	24217
@NP	transplantation	24231
@NP	the epicentre of a contusion lesion	24252
@NP	the epicentre	24252
@NP	a contusion lesion	24269
@NP	a 60 % survival rate	24300
@NP	the lesion -LRB- Pearse et al. , 2007 -RRB-	24348
@NP	the lesion	24348
@NP	Pearse	24360
@NP	et al. , 2007	24367
@NP	et al.	24367
@NP	2007	24375
@NP	In vitro experiments	24382
@NP	apoptosis of OECs	24428
@NP	apoptosis	24428
@NP	OECs	24441
@NP	acutely injured spinal cord explants	24496
@NP	delayed injury explants -LRB- Woodhouse et al. , 2005 -RRB-	24545
@NP	delayed injury explants	24545
@NP	Woodhouse	24570
@NP	et al. , 2005	24580
@NP	et al.	24580
@NP	2005	24588
@NP	3.2	24595
@NP	hOECs	24600
@NP	locomotor ability	24615
@NP	controls	24645
@NP	our results	24667
@NP	the injury	24691
@NP	the dorsal surface of the spinal cord	24721
@NP	the dorsal surface	24721
@NP	the spinal cord	24743
@NP	the impact	24765
@NP	Tissue	24786
@NP	deeper levels	24805
@NP	the spinal cord	24830
@NP	injury severity	24858
@NP	the impact site	24901
@NP	the most spared tissue located ventrally as described by Basso	24922
@NP	the most	24922
@NP	tissue	24938
@NP	Basso	24979
@NP	et al. -LRB- 1996 -RRB-	24985
@NP	et al.	24985
@NP	1996	24993
@NP	accordance with this	25003
@NP	accordance	25003
@NP	this	25019
@NP	most animals in our study	25025
@NP	most animals	25025
@NP	our study	25041
@NP	weight support	25065
@NP	stance	25083
@NP	some degree of weight	25093
@NP	some degree	25093
@NP	weight	25108
@NP	2 weeks	25137
@NP	injury and this improved over the following 4 weeks	25151
@NP	injury	25151
@NP	this improved over the following 4 weeks	25162
@NP	this	25162
@NP	the following 4 weeks	25181
@NP	their higher BBB scores	25220
@NP	hOEC transplanted animals had more `` consistent '' hind-fore limb co-ordination	25245
@NP	hOEC transplanted animals	25245
@NP	more `` consistent '' hind-fore limb co-ordination	25275
@NP	`` occasional '' or `` frequent ''	25334
@NP	the control groups , and more parallel paw placement	25365
@NP	the control groups	25365
@NP	and more parallel paw placement	25385
@NP	a rotated placement for the controls	25430
@NP	a rotated placement	25430
@NP	the controls	25454
@NP	These differences in locomotor ability	25468
@NP	These differences	25468
@NP	locomotor ability	25489
@NP	the horizontal ladder task -LRB- Metz and Whishaw , 2002 -RRB-	25529
@NP	the horizontal ladder task	25529
@NP	Metz and Whishaw , 2002	25557
@NP	Metz	25557
@NP	Whishaw , 2002	25566
@NP	Whishaw	25566
@NP	2002	25575
@NP	the open field assessment	25593
@NP	Basso	25620
@NP	et al. , 1995	25626
@NP	et al.	25626
@NP	1995	25634
@NP	there	25655
@NP	differential sparing	25665
@NP	tissue	25689
@NP	the hOEC transplanted animals	25700
@NP	the controls particularly in the central to ventral parts of the cord	25742
@NP	the controls	25742
@NP	the central to ventral parts of the cord	25771
@NP	the central to ventral parts	25771
@NP	the cord	25803
@NP	the rat	25816
@NP	descending spinal tracts located in this region	25825
@NP	descending spinal tracts	25825
@NP	this region	25861
@NP	the medullary and pontine reticulospinal tracts	25881
@NP	the medial and lateral vestibulospinal tracts	25930
@NP	raphespinal fibres	25980
@NP	the raphe obscurus and pallidus nuclei -LRB- Watson et al. , 2009 -RRB-	26015
@NP	the raphe obscurus	26015
@NP	pallidus nuclei -LRB- Watson et al. , 2009 -RRB-	26038
@NP	pallidus nuclei	26038
@NP	Watson	26055
@NP	et al. , 2009	26062
@NP	et al.	26062
@NP	2009	26070
@NP	These tracts	26077
@NP	the maintenance of posture and balance	26106
@NP	the maintenance	26106
@NP	posture and balance	26125
@NP	walking	26152
@NP	the initiation and maintenance	26164
@NP	locomotion -LRB- Fouad and Pearson , 2004 -RRB-	26198
@NP	locomotion	26198
@NP	Fouad and Pearson , 2004	26210
@NP	Fouad	26210
@NP	Pearson , 2004	26220
@NP	Pearson	26220
@NP	2004	26229
@NP	Plasticity or regeneration of these fibre tracts	26236
@NP	Plasticity or regeneration	26236
@NP	these fibre tracts	26266
@NP	functional hindlimb recovery	26314
@NP	spinal lesions	26353
@NP	Ballermann and Fouad	26369
@NP	2006	26391
@NP	Ito et al. , 1999 ; Lopez-Vales et al. , 2007 ; Lu et al. , 2002 ; Boido et al.	26397
@NP	Ito	26397
@NP	et al. , 1999 ; Lopez-Vales et al. , 2007 ; Lu et al. , 2002 ; Boido et al.	26401
@NP	et al. , 1999	26401
@NP	et al.	26401
@NP	1999	26409
@NP	Lopez-Vales et al. , 2007	26415
@NP	Lopez-Vales	26415
@NP	et al. , 2007	26427
@NP	et al.	26427
@NP	2007	26435
@NP	Lu et al. , 2002	26441
@NP	Lu	26441
@NP	et al. , 2002	26444
@NP	et al.	26444
@NP	2002	26452
@NP	Boido et al.	26458
@NP	Boido	26458
@NP	et al.	26464
@NP	2009	26472
@NP	the dorsal columns and dorsolateral tissue	26485
@NP	the corticospinal and rubrospinal tracts	26539
@NP	our injury model	26613
@NP	the transplanted hOECs	26631
@NP	survival or plasticity of axons	26671
@NP	survival or plasticity	26671
@NP	axons	26697
@NP	the lateral , ventrolateral and ventral parts of the cord	26706
@NP	the lateral , ventrolateral and ventral parts	26706
@NP	the cord	26754
@NP	the locomotor improvements seen	26775
@NP	the locomotor improvements	26775
@NP	3.3	26808
@NP	hOECs	26813
@NP	histological measures of injury	26827
@NP	histological measures	26827
@NP	injury	26852
@NP	controls	26871
@NP	We	26880
@NP	hOECs from olfactory mucosa	26899
@NP	hOECs	26899
@NP	olfactory mucosa	26910
@NP	lesion size and cavity area within the lesion	26934
@NP	lesion size and cavity area	26934
@NP	the lesion	26969
@NP	This	26981
@NP	findings after transplantation of mouse mucosal OECs	27005
@NP	findings	27005
@NP	transplantation of mouse mucosal OECs	27020
@NP	transplantation	27020
@NP	mouse mucosal OECs	27039
@NP	a rat	27063
@NP	dorsolateral spinal cord injury -LRB- Ramer et al. , 2004 -RRB-	27069
@NP	dorsolateral spinal cord injury	27069
@NP	Ramer	27102
@NP	et al. , 2004	27108
@NP	et al.	27108
@NP	2004	27116
@NP	rat olfactory bulb OECs	27127
@NP	rat	27127
@NP	olfactory bulb OECs	27131
@NP	a moderate contusion lesion	27154
@NP	Plant	27183
@NP	et al. , 2003 ; Takami et al. , 2002	27189
@NP	et al.	27189
@NP	2003 ; Takami et al.	27197
@NP	2003	27197
@NP	Takami et al.	27203
@NP	Takami	27203
@NP	et al.	27210
@NP	2002	27218
@NP	other studies of rat olfactory bulb OECs	27236
@NP	other studies	27236
@NP	rat olfactory bulb OECs	27253
@NP	contusions -LRB- Barakat et al. , 2005 ; Pearse et al. , 2007 -RRB-	27295
@NP	contusions	27295
@NP	Barakat	27307
@NP	et al. , 2005 ; Pearse et al. , 2007	27315
@NP	et al.	27315
@NP	2005 ; Pearse et al.	27323
@NP	2005	27323
@NP	Pearse et al.	27329
@NP	Pearse	27329
@NP	et al.	27336
@NP	2007	27344
@NP	the present study	27354
@NP	the hOEC graft	27373
@NP	the host tissue	27413
@NP	H&E , in agreement with the findings of Takami	27447
@NP	H&E	27447
@NP	agreement with the findings of Takami	27455
@NP	agreement	27455
@NP	the findings of Takami	27470
@NP	the findings	27470
@NP	Takami	27486
@NP	et al. -LRB- 2002 -RRB-	27493
@NP	et al.	27493
@NP	2002	27501
@NP	fluorescence immunochemistry	27516
@NP	cavity-filling cells	27563
@NP	the hOECs	27609
@NP	the periphery of the lesion	27634
@NP	the periphery	27634
@NP	the lesion	27651
@NP	others -LRB- Barakat et al. , 2005 ; Pearse et al. , 2007 -RRB-	27678
@NP	others	27678
@NP	Barakat	27686
@NP	et al. , 2005 ; Pearse et al. , 2007	27694
@NP	et al.	27694
@NP	2005 ; Pearse et al.	27702
@NP	2005	27702
@NP	Pearse et al.	27708
@NP	Pearse	27708
@NP	et al.	27715
@NP	2007	27723
@NP	The presence of hOEC at the edge of the lesion	27730
@NP	The presence	27730
@NP	hOEC at the edge of the lesion	27746
@NP	hOEC	27746
@NP	the edge of the lesion	27754
@NP	the edge	27754
@NP	the lesion	27766
@NP	reductions in GFAP intensity	27797
@NP	reductions	27797
@NP	GFAP intensity	27811
@NP	the lesion	27838
@NP	hOECs	27865
@NP	the injury-induced astrogliosis	27888
@NP	coculture	27924
@NP	astrocytes	27939
@NP	OECs	27950
@NP	astrogliosis	27962
@NP	a `` wound injury '' model -LRB- O'Toole et al. , 2007 -RRB-	27978
@NP	a `` wound injury '' model	27978
@NP	O'Toole	28002
@NP	et al. , 2007	28010
@NP	et al.	28010
@NP	2007	28018
@NP	A previous study	28025
@NP	histological and behavioural recovery	28051
@NP	OEC transplantation	28095
@NP	the contusion injury of the spinal cord -LRB- Plant et al. , 2003 -RRB-	28120
@NP	the contusion injury	28120
@NP	the spinal cord -LRB- Plant et al. , 2003 -RRB-	28144
@NP	the spinal cord	28144
@NP	Plant	28161
@NP	et al. , 2003	28167
@NP	et al.	28167
@NP	2003	28175
@NP	That study	28182
@NP	OECs obtained from the adult rat olfactory bulb	28198
@NP	OECs	28198
@NP	the adult rat olfactory bulb	28217
@NP	similar histological recovery as shown here for hOECs from the olfactory mucosa	28252
@NP	similar histological recovery	28252
@NP	hOECs from the olfactory mucosa	28300
@NP	hOECs	28300
@NP	the olfactory mucosa	28311
@NP	Plant et al. -LRB- 2003 -RRB-	28333
@NP	Plant et al.	28333
@NP	Plant	28333
@NP	et al.	28339
@NP	2003	28347
@NP	improved locomotor ability	28367
@NP	significant axonal sparing	28411
@NP	regeneration	28439
@NP	OECs	28457
@NP	the lesion site	28485
@NP	7 days	28501
@NP	the contusion	28514
@NP	Demonstration of efficacy in contusion injuries	28529
@NP	Demonstration	28529
@NP	efficacy in contusion injuries	28546
@NP	efficacy	28546
@NP	contusion injuries	28558
@NP	an important pre-clinical outcome	28580
@NP	contusions	28622
@NP	the most common type of human injury	28637
@NP	the most common type	28637
@NP	human injury	28661
@NP	all other studies of OEC transplantation	28678
@NP	all other studies	28678
@NP	OEC transplantation	28699
@NP	either small discrete spinal cord lesions or complete spinal cord transections	28729
@NP	spinal cord lesions	28751
@NP	Guest	28809
@NP	et al. , 2008	28815
@NP	et al.	28815
@NP	2008	28823
@NP	Keyvan-Fouladi et al. , 2003	28829
@NP	Keyvan-Fouladi	28829
@NP	et al. , 2003	28844
@NP	et al.	28844
@NP	2003	28852
@NP	Li et al. , 1997	28858
@NP	Li	28858
@NP	et al. , 1997	28861
@NP	et al.	28861
@NP	1997	28869
@NP	Lopez-Vales et al. , 2007	28875
@NP	Lopez-Vales	28875
@NP	et al. , 2007	28887
@NP	et al.	28887
@NP	2007	28895
@NP	Lu et al. , 2002	28901
@NP	Lu	28901
@NP	et al. , 2002	28904
@NP	et al.	28904
@NP	2002	28912
@NP	3.4	28919
@NP	Mechanism of hOEC action	28924
@NP	Mechanism	28924
@NP	hOEC action	28937
@NP	We	28949
@NP	significant improvements	28969
@NP	functional and histological outcomes	28997
@NP	transplantation of hOECs	29040
@NP	transplantation	29040
@NP	hOECs	29059
@NP	the contusion site	29070
@NP	there	29093
@NP	no evidence	29103
@NP	the OECs	29120
@NP	the surrounding parenchyma	29143
@NP	axons	29209
@NP	there	29219
@NP	there	29229
@NP	evidence for axons coursing through the lesion/transplant site	29235
@NP	evidence	29235
@NP	axons coursing through the lesion/transplant site	29248
@NP	axons	29248
@NP	the lesion/transplant site	29271
@NP	We	29299
@NP	the hOECs	29316
@NP	growth factors and cytokines released into the surrounding tissues	29378
@NP	growth factors and cytokines	29378
@NP	the surrounding tissues	29421
@NP	OECs	29446
@NP	soluble factors	29459
@NP	neurotrophins	29486
@NP	neurite	29514
@NP	the injured spinal cord	29548
@NP	Chuah et al. , 2004 ; Chung et al. , 2004 ; Woodhouse et al. , 2005	29573
@NP	Chuah	29573
@NP	et al. , 2004 ; Chung et al. , 2004 ; Woodhouse et al. , 2005	29579
@NP	et al. , 2004	29579
@NP	et al.	29579
@NP	2004	29587
@NP	Chung et al. , 2004	29593
@NP	Chung	29593
@NP	et al. , 2004	29599
@NP	et al.	29599
@NP	2004	29607
@NP	Woodhouse et al. , 2005	29613
@NP	Woodhouse	29613
@NP	et al. , 2005	29623
@NP	et al.	29623
@NP	2005	29631
@NP	Many studies	29638
@NP	the regenerative and anti-apoptotic effects of neurotrophic factors	29669
@NP	the regenerative and anti-apoptotic effects	29669
@NP	neurotrophic factors	29716
@NP	spinal cord repair	29740
@NP	Bregman	29760
@NP	et al. , 2002 ; Jin et al. , 2002 ; Lo et al. , 2008 ; Vavrek et al. , 2006	29768
@NP	et al. , 2002	29768
@NP	et al.	29768
@NP	2002	29776
@NP	Jin et al. , 2002	29782
@NP	Jin	29782
@NP	et al. , 2002	29786
@NP	et al.	29786
@NP	2002	29794
@NP	Lo et al. , 2008	29800
@NP	Lo	29800
@NP	et al. , 2008	29803
@NP	et al.	29803
@NP	2008	29811
@NP	Vavrek et al. , 2006	29817
@NP	Vavrek	29817
@NP	et al. , 2006	29824
@NP	et al.	29824
@NP	2006	29832
@NP	Recent gene expression analyses	29839
@NP	OECs	29887
@NP	a large range	29905
@NP	genes involved in wound repair , extracellular matrix formation	29922
@NP	genes	29922
@NP	wound repair , extracellular matrix formation	29940
@NP	wound repair	29940
@NP	extracellular matrix formation	29954
@NP	cell adhesion	29986
@NP	Franssen et al. , 2008 ; Kafitz and Greer , 1998 ; Vincent et al. , 2005	30001
@NP	Franssen	30001
@NP	et al. , 2008 ; Kafitz and Greer , 1998 ; Vincent et al. , 2005	30010
@NP	et al. , 2008	30010
@NP	et al.	30010
@NP	2008	30018
@NP	Kafitz and Greer , 1998	30024
@NP	Kafitz and Greer	30024
@NP	1998	30042
@NP	Vincent et al. , 2005	30048
@NP	Vincent	30048
@NP	et al. , 2005	30056
@NP	et al.	30056
@NP	2005	30064
@NP	inflammatory responses -LRB- Vincent et al. , 2005 -RRB-	30074
@NP	inflammatory responses	30074
@NP	Vincent	30098
@NP	et al. , 2005	30106
@NP	et al.	30106
@NP	2005	30114
@NP	The reduction	30121
@NP	astrogliosis	30138
@NP	the hOEC transplanted animals suggests another potential mechanism of action	30154
@NP	the hOEC	30154
@NP	transplanted animals	30163
@NP	another potential mechanism of action	30193
@NP	another potential mechanism	30193
@NP	action	30224
@NP	modulation of the inflammation in the spinal cord	30240
@NP	modulation	30240
@NP	the inflammation in the spinal cord	30254
@NP	the inflammation	30254
@NP	the spinal cord	30274
@NP	Inflammation	30291
@NP	an important process that removes cellular debris after injury	30307
@NP	an important process	30307
@NP	cellular debris	30341
@NP	injury	30363
@NP	activated neutrophils and macrophages/microglia	30397
@NP	activated neutrophils	30397
@NP	macrophages/microglia	30423
@NP	toxic cytokines	30469
@NP	healthy tissue	30497
@NP	secondary damage	30534
@NP	This	30552
@NP	a major problem following spinal cord injury -LRB- Fitch et al. , 1999 -RRB-	30560
@NP	a major problem	30560
@NP	spinal cord injury -LRB- Fitch et al. , 1999 -RRB-	30586
@NP	spinal cord injury	30586
@NP	Fitch	30606
@NP	et al. , 1999	30612
@NP	et al.	30612
@NP	1999	30620
@NP	The reduction of astrocytes at the lesion site	30627
@NP	The reduction	30627
@NP	astrocytes at the lesion site	30644
@NP	astrocytes	30644
@NP	the lesion site	30658
@NP	a reduced inflammatory response to the injury	30693
@NP	a reduced inflammatory response	30693
@NP	the injury	30728
@NP	the issue	30743
@NP	a deeper analysis of inflammatory cells and molecules	30762
@NP	a deeper analysis	30762
@NP	inflammatory cells and molecules	30783
@NP	example	30821
@NP	there	30830
@NP	no obvious difference	30840
@NP	macrophage / microglia density at the lesion in the present study	30865
@NP	macrophage	30865
@NP	microglia density at the lesion in the present study	30877
@NP	microglia density	30877
@NP	the lesion in the present study	30898
@NP	the lesion	30898
@NP	the present study	30912
@NP	a timecourse analysis	30934
@NP	dynamic changes	30976
@NP	the early stages and wound and repair responses	30999
@NP	the early stages	30999
@NP	wound and repair responses	31020
@NP	Lopez-Vales	31048
@NP	et al. -LRB- 2004 -RRB-	31060
@NP	et al.	31060
@NP	2004	31068
@NP	an earlier higher recruitment of microglia/macrophages	31087
@NP	an earlier higher recruitment	31087
@NP	microglia/macrophages	31120
@NP	rat OEC	31145
@NP	the first 2 weeks post-injury compared to DMEM	31163
@NP	the first 2 weeks	31163
@NP	DMEM	31205
@NP	animals	31219
@NP	significant improvements	31233
@NP	function and tissue sparing	31261
@NP	Experimental procedures 4.1 .	31294
@NP	Experimental procedures	31294
@NP	4.1	31318
@NP	Biopsy and cell culture of human OECs Olfactory mucosa	31323
@NP	Biopsy and cell culture	31323
@NP	human OECs Olfactory mucosa	31350
@NP	human OECs	31350
@NP	Olfactory mucosa	31361
@NP	biopsy	31394
@NP	human volunteers	31406
@NP	routine nasal surgery -LRB- septoplasty or turbinectomy -RRB-	31430
@NP	routine nasal surgery	31430
@NP	septoplasty or turbinectomy	31453
@NP	septoplasty	31453
@NP	turbinectomy	31468
@NP	general anesthesia -LRB- Feron et al. , 1998 -RRB-	31488
@NP	general anesthesia	31488
@NP	Feron	31508
@NP	et al. , 1998	31514
@NP	et al.	31514
@NP	1998	31522
@NP	All biopsies	31529
@NP	informed consent	31561
@NP	a protocol	31584
@NP	the human ethics committees	31607
@NP	Griffith University and the Brisbane Private Hospital	31638
@NP	Griffith University	31638
@NP	the Brisbane Private Hospital	31662
@NP	Brisbane , Australia , in accordance with the guidelines of the National Health	31693
@NP	Brisbane , Australia ,	31693
@NP	accordance with the guidelines of the National Health	31717
@NP	accordance	31717
@NP	the guidelines of the National Health	31733
@NP	the guidelines	31733
@NP	the National Health	31751
@NP	Medical Research Council of Australia	31775
@NP	Medical Research Council	31775
@NP	Australia	31803
@NP	The biopsies , fromthe posterior septumclose to the cribiform plate ,	31814
@NP	The biopsies	31814
@NP	fromthe posterior septumclose to the cribiform plate	31828
@NP	fromthe posterior septumclose	31828
@NP	the cribiform plate	31861
@NP	ice	31909
@NP	Dulbecco	31916
@NP	Eagle 's medium/Ham F12 -LRB- DMEM/F12 ; JRH -RRB-	31935
@NP	Eagle 's medium/Ham F12	31935
@NP	Eagle 's	31935
@NP	DMEM/F12 ; JRH	31959
@NP	DMEM/F12	31959
@NP	JRH	31969
@NP	hOECs	31978
@NP	Bianco	32012
@NP	et al. , 2004	32019
@NP	et al.	32019
@NP	2004	32027
@NP	the	32043
@NP	tissuewas	32056
@NP	45 min	32080
@NP	37 °C	32090
@NP	Dispase II	32099
@NP	2.4 U/ml in Puck 's solution ; Boehringer , Mannheim , Germany	32111
@NP	2.4 U/ml	32111
@NP	Puck 's solution ; Boehringer , Mannheim , Germany	32123
@NP	Puck 's solution	32123
@NP	Puck 's	32123
@NP	Boehringer , Mannheim , Germany	32140
@NP	the lamina propria	32184
@NP	the epithelium with a microspatula	32222
@NP	the epithelium	32222
@NP	a microspatula	32242
@NP	Hank 's balanced salt solution -LRB- HBSS ; JRH -RRB-	32271
@NP	Hank 's balanced salt solution	32271
@NP	Hank 's	32271
@NP	HBSS ; JRH	32302
@NP	HBSS	32302
@NP	JRH	32308
@NP	The lamina propria	32314
@NP	smaller 40 μm pieces	32351
@NP	smaller	32351
@NP	40 μm pieces	32359
@NP	a McIlwain tissue chopper	32378
@NP	Brinkman Instruments	32405
@NP	Inc. , Westbury	32427
@NP	New York	32443
@NP	collagenase -LRB- 0.25 % ;	32470
@NP	collagenase	32470
@NP	0.25 %	32483
@NP	type I ; Sigma , St.	32490
@NP	type I	32490
@NP	Sigma , St.	32498
@NP	Louis , MO -RRB- in DMEM/F12 for 10 min at 37 °C .	32509
@NP	Louis , MO -RRB- in DMEM/F12 for 10	32509
@NP	Louis , MO -RRB-	32509
@NP	Louis	32509
@NP	DMEM/F12 for 10	32523
@NP	DMEM/F12	32523
@NP	10	32536
@NP	min at 37 °C	32538
@NP	min	32538
@NP	37 °C	32545
@NP	The tissue	32551
@NP	single cells	32596
@NP	trituration	32612
@NP	HBSS	32643
@NP	The cells	32649
@NP	centrifugation	32676
@NP	DMEM/F12	32710
@NP	foetal calf serum -LRB- FCS , 10 % -RRB-	32737
@NP	foetal calf serum	32737
@NP	FCS	32756
@NP	10 %	32761
@NP	poly-L-lysinecoated tissue culture flasks -LRB- 1 μg/cm2 ; Sigma -RRB-	32782
@NP	poly-L-lysinecoated tissue culture flasks	32782
@NP	1 μg/cm2 ; Sigma	32825
@NP	1 μg/cm2	32825
@NP	Sigma	32835
@NP	Cells	32843
@NP	this medium at 37 °C / 5 % CO2 for 48 h	32863
@NP	37 °C	32878
@NP	5 % CO2 for 48	32884
@NP	5 % CO2	32884
@NP	48	32895
@NP	the medium	32913
@NP	DMEM/F12 supplemented with neurotrophin-3	32939
@NP	DMEM/F12	32939
@NP	neurotrophin-3	32966
@NP	50 ng/ml ; Alamone Labs	32982
@NP	50 ng/ml	32982
@NP	Alamone Labs	32992
@NP	Jerusalem , Israel	33006
@NP	Jerusalem	33006
@NP	Israel	33017
@NP	a process that enhances OEC proliferation -LRB- Bianco et al. , 2004 -RRB-	33026
@NP	a process	33026
@NP	OEC proliferation	33050
@NP	Bianco	33069
@NP	et al. , 2004	33076
@NP	et al.	33076
@NP	2004	33084
@NP	a cell line	33101
@NP	human recombinant green fluorescent protein -LRB- hrGFP -RRB-	33132
@NP	human recombinant green fluorescent protein	33132
@NP	hrGFP	33177
@NP	cells	33185
@NP	the pFB-hrGFP retroviral supernatant -LRB- Stratagene , Catalogue # 972002 -RRB-	33212
@NP	the pFB-hrGFP retroviral supernatant	33212
@NP	Stratagene , Catalogue # 972002	33250
@NP	Stratagene , Catalogue	33250
@NP	# 972002	33272
@NP	the manufacturer 's instructions	33294
@NP	the manufacturer 's	33294
@NP	Fluorescence	33327
@NP	cell sorting -LRB- FACS -RRB-	33350
@NP	cell sorting	33350
@NP	FACS	33364
@NP	a near > 99 % pure population of cells expressing hrGFP	33400
@NP	a near > 99 % pure population	33400
@NP	99 %	33408
@NP	cells expressing hrGFP	33431
@NP	cells	33431
@NP	hrGFP	33448
@NP	FACS , cultures	33461
@NP	FACS	33461
@NP	cultures	33467
@NP	approximately 80	33490
@NP	90 % confluence	33508
@NP	cyropreservation	33541
@NP	incubation in Trypsin-EDTA -LRB- 0.25 % Trypsin , 1 mM EDTA ; JRH -RRB-	33561
@NP	incubation	33561
@NP	Trypsin-EDTA -LRB- 0.25 % Trypsin , 1 mM EDTA ; JRH -RRB-	33575
@NP	Trypsin-EDTA	33575
@NP	0.25 % Trypsin	33589
@NP	0.25 %	33589
@NP	Trypsin	33595
@NP	1 mM EDTA ; JRH	33604
@NP	1 mM EDTA	33604
@NP	JRH	33615
@NP	solution	33620
@NP	5 min at 37 °C	33633
@NP	5 min	33633
@NP	37 °C	33642
@NP	5 % CO2 followed by centrifugation to pelletise the cells	33648
@NP	5 % CO2	33648
@NP	centrifugation	33667
@NP	the cells	33695
@NP	The cell pellet	33706
@NP	cryo-storage medium	33746
@NP	90 % FCS and 10 % dimethyl sulfoxide -LRB- DMSO -RRB-	33780
@NP	90 % FCS	33780
@NP	10 % dimethyl sulfoxide -LRB- DMSO -RRB-	33792
@NP	10 % dimethyl sulfoxide	33792
@NP	DMSO	33816
@NP	4 °C	33825
@NP	Aliquots of cell suspension -LRB- 0.5 ml each -RRB-	33831
@NP	Aliquots of cell suspension	33831
@NP	Aliquots	33831
@NP	cell suspension	33843
@NP	0.5 ml each	33860
@NP	0.5 ml	33860
@NP	each	33867
@NP	cryotubes -LRB- Nunc -RRB-	33893
@NP	cryotubes	33893
@NP	Nunc	33904
@NP	ice	33936
@NP	liquid nitrogen for long-term storage	33963
@NP	liquid nitrogen	33963
@NP	long-term storage	33983
@NP	cryopreserved cells	34012
@NP	cryotubes	34033
@NP	liquid nitrogen	34061
@NP	a 37 °C water bath	34105
@NP	thaw	34127
@NP	1 ml of pre-warmed -LRB- 37 °C -RRB- DMEM/F12 + 10 % FCS	34144
@NP	1 ml	34144
@NP	pre-warmed -LRB- 37 °C -RRB- DMEM/F12 + 10 % FCS	34152
@NP	pre-warmed -LRB- 37 °C -RRB- DMEM/F12 + 10 %	34152
@NP	pre-warmed -LRB- 37 °C -RRB- DMEM/F12	34152
@NP	37 °C	34164
@NP	10 %	34182
@NP	a final volume of 1.5 ml	34213
@NP	a final volume	34213
@NP	1.5 ml	34231
@NP	The cell suspension	34239
@NP	10 ml of prewarmed DMEM/F12 +10 % FCS	34292
@NP	10 ml	34292
@NP	prewarmed DMEM/F12 +10 % FCS	34301
@NP	prewarmed DMEM/F12	34301
@NP	+10 % FCS	34319
@NP	200g for 10 min	34347
@NP	200g	34347
@NP	10 min	34356
@NP	The pellet	34364
@NP	DMEM/F12 +10 % FCS	34395
@NP	DMEM/F12	34395
@NP	+10 % FCS	34403
@NP	transplantation experiments	34465
@NP	hOEC cultures	34494
@NP	the University of New South Wales on the day prior to the experiment	34528
@NP	the University	34528
@NP	New South Wales on the day prior to the experiment	34546
@NP	New South Wales	34546
@NP	the day prior to the experiment	34565
@NP	the day	34565
@NP	the experiment	34582
@NP	courier	34600
@NP	ambient temperature	34611
@NP	transplantation cells	34641
@NP	the vital	34693
@NP	Trypan Blue	34707
@NP	a concentration of 15 ×	34740
@NP	a concentration	34740
@NP	15 ×	34759
@NP	104 cells/μl in DMEM/F12 +10 % FCS	34762
@NP	104 cells/μl	34762
@NP	DMEM/F12 +10 % FCS	34778
@NP	DMEM/F12	34778
@NP	+10 % FCS	34786
@NP	4.2	34796
@NP	Animals 24 inbred athymic rats	34801
@NP	Animals	34801
@NP	24 inbred athymic rats	34809
@NP	CBH-rnu/Arc , female	34833
@NP	CBH-rnu/Arc	34833
@NP	female	34846
@NP	8 -- 9 weeks old	34854
@NP	8	34854
@NP	9 weeks old	34856
@NP	the Animal Resources Centre -LRB- Perth , Australia -RRB-	34888
@NP	the Animal Resources Centre	34888
@NP	Perth	34917
@NP	Australia	34924
@NP	They	34936
@NP	sterilized cages	34956
@NP	an air filter and sterile beddingmaterials	34987
@NP	an air filter	34987
@NP	sterile beddingmaterials	35005
@NP	12:12-h light	35048
@NP	dark cycle , with free access to sterilized water	35062
@NP	dark cycle	35062
@NP	free access to sterilized water	35079
@NP	free access	35079
@NP	sterilized water	35094
@NP	irradiated food throughout the experiment	35115
@NP	irradiated food	35115
@NP	the experiment	35142
@NP	All animal procedures	35158
@NP	approval	35200
@NP	the University of New South Wales Animal Care and Ethics Committee	35214
@NP	the University	35214
@NP	New South Wales Animal Care and Ethics Committee	35232
@NP	New South Wales Animal Care	35232
@NP	Ethics Committee	35264
@NP	4.3	35282
@NP	Spinal cord injury Rats	35287
@NP	ketamine : xylazine -LRB- 100:10 mg/kg , IP -RRB-	35334
@NP	ketamine	35334
@NP	xylazine	35343
@NP	100:10 mg/kg	35353
@NP	IP	35367
@NP	a homeothermic blanket -LRB- body temperature maintained at 37 °C ± 1 °C -RRB-	35385
@NP	a homeothermic blanket	35385
@NP	body temperature	35409
@NP	37 °C ± 1 °C	35440
@NP	37 °C ±	35440
@NP	1 °C	35446
@NP	An incision	35453
@NP	the dorsal midline skin	35477
@NP	the mid	35506
@NP	the low thoracic region	35517
@NP	subsequent layers of connective tissue and muscle	35545
@NP	subsequent layers	35545
@NP	connective tissue and muscle	35566
@NP	the spinal column	35620
@NP	A bilateral laminectomy	35639
@NP	the T10 vertebrae	35680
@NP	Animals	35699
@NP	a moderate contusion injury	35725
@NP	the MASCIS weight drop device	35759
@NP	New York University -LRB- 12.5 mm , 10 g , -RRB-	35802
@NP	New York University	35802
@NP	12.5 mm	35823
@NP	10 g	35832
@NP	The impact height , velocity and compression	35840
@NP	the compression rate	35902
@NP	Rats	35935
@NP	the study	35959
@NP	they	35972
@NP	a compression rate	35981
@NP	more than two standard deviations from the group mean	36000
@NP	more than two standard deviations	36000
@NP	the group mean	36039
@NP	The muscles and the skin	36055
@NP	The muscles	36055
@NP	the skin	36071
@NP	layers	36103
@NP	animals	36127
@NP	antibiotics -LRB- cephalothin sodium 100 mg/mL , 0.1 ml -RRB-	36146
@NP	antibiotics	36146
@NP	cephalothin sodium	36159
@NP	100 mg/mL , 0.1 ml	36178
@NP	100 mg/mL	36178
@NP	0.1 ml	36189
@NP	analgesics -LRB- carprofen 50 mg/mL , 0.01 ml -RRB-	36198
@NP	analgesics	36198
@NP	carprofen 50 mg/mL , 0.01 ml	36210
@NP	carprofen 50 mg/mL	36210
@NP	0.01 ml	36230
@NP	supplementary fluid -LRB- Hartman 's replacement solution 2 ml -RRB-	36243
@NP	supplementary fluid	36243
@NP	Hartman 's replacement solution 2 ml	36264
@NP	Hartman 's replacement solution	36264
@NP	Hartman 's	36264
@NP	2 ml	36295
@NP	3 days	36317
@NP	Bladders	36325
@NP	the normal voiding response	36364
@NP	Antibiotics	36402
@NP	the urine	36435
@NP	4.4	36456
@NP	hOEC transplantation	36461
@NP	One week	36482
@NP	the spinal cord contusion injury	36497
@NP	animals	36531
@NP	above and the T10 lesion site re-exposed	36563
@NP	above	36563
@NP	the T10 lesion site re-exposed	36573
@NP	the T10 lesion site	36573
@NP	The vertebral column	36605
@NP	clamps	36647
@NP	the T9 and T11 spinous process	36657
@NP	a 5-μl syringe -LRB- 26G , SGE , Australia -RRB- attached to a micromanipulater	36692
@NP	a 5-μl syringe -LRB- 26G , SGE , Australia -RRB-	36692
@NP	a 5-μl syringe	36692
@NP	26G	36708
@NP	SGE	36713
@NP	Australia	36718
@NP	a micromanipulater	36741
@NP	hOECs in solution	36779
@NP	hOECs	36779
@NP	solution	36788
@NP	the spinal cord lesion	36802
@NP	A total of 1 × 106 hOECs	36826
@NP	A total	36826
@NP	1 × 106 hOECs	36837
@NP	1 ×	36837
@NP	106 hOECs	36839
@NP	7 μl of DMEM/F12 + 10 % FCS	36867
@NP	7 μl	36867
@NP	DMEM/F12 + 10 % FCS	36875
@NP	DMEM/F12	36875
@NP	10 % FCS	36886
@NP	5 μl of hOEC solution	36895
@NP	5 μl	36895
@NP	hOEC solution	36903
@NP	the centre of the lesion over 5 min	36935
@NP	the centre	36935
@NP	the lesion over 5 min	36949
@NP	the lesion	36949
@NP	5 min	36965
@NP	1 μl	36971
@NP	1 mm rostral	36989
@NP	1 μl	37006
@NP	1 mm caudal on the midline	37024
@NP	1 mm caudal	37024
@NP	the midline	37038
@NP	a depth of 0.5 mm	37053
@NP	a depth	37053
@NP	0.5 mm	37064
@NP	Control animals	37072
@NP	the same volume of culture media	37097
@NP	the same volume	37097
@NP	culture media	37116
@NP	cells , injected into the same sites	37143
@NP	cells	37143
@NP	the same sites	37164
@NP	injection	37186
@NP	syringes	37197
@NP	place for a further 3 min	37219
@NP	place	37219
@NP	a further 3 min	37229
@NP	leakage	37255
@NP	removal	37266
@NP	4.5	37275
@NP	Behavioural assessments Each animal	37280
@NP	Behavioural assessments	37280
@NP	Each animal	37304
@NP	the open field apparatus	37338
@NP	the horizontal ladder	37382
@NP	surgery	37413
@NP	the spinal cord contusion	37432
@NP	the animals	37458
@NP	the open field apparatus at day 1 post-contusion and then weekly for 6 weeks	37487
@NP	the open field apparatus at day 1 post-contusion	37487
@NP	the open field apparatus	37487
@NP	day 1 post-contusion	37515
@NP	then weekly for 6 weeks	37540
@NP	then weekly	37540
@NP	6 weeks	37556
@NP	Animals	37565
@NP	the horizontal ladder	37593
@NP	6 weeks	37618
@NP	All sessions	37642
@NP	digital cameras linked to a FileMaker Pro database	37675
@NP	digital cameras	37675
@NP	a FileMaker Pro database	37701
@NP	FileMaker	37727
@NP	Pro 7.0 v3 , FileMaker Inc , 1984 -- 2007 , Ca	37737
@NP	Pro	37737
@NP	7.0 v3 , FileMaker Inc , 1984 -- 2007 , Ca	37741
@NP	7.0 v3	37741
@NP	FileMaker Inc	37749
@NP	1984 -- 2007	37764
@NP	Ca	37775
@NP	2 min -LRB- open field -RRB-	37783
@NP	2 min	37783
@NP	open field	37789
@NP	three passes of the horizontal ladder	37808
@NP	three passes	37808
@NP	the horizontal ladder	37824
@NP	Scoring	37847
@NP	2 independent observers	37872
@NP	the treatment group	37910
@NP	the digital recordings which could be analysed frame by frame when necessary	37936
@NP	the digital recordings	37936
@NP	frame by frame	37983
@NP	frame	37983
@NP	frame	37992
@NP	Averaged scores	38014
@NP	the final score for each trial	38043
@NP	the final score	38043
@NP	each trial	38063
@NP	4.5.1	38075
@NP	field assessments	38087
@NP	The BBB rating scale -LRB- Basso et al. , 1995 -RRB-	38105
@NP	The BBB rating scale	38105
@NP	Basso	38127
@NP	et al. , 1995	38133
@NP	et al.	38133
@NP	1995	38141
@NP	open field assessments	38160
@NP	this rating scale	38193
@NP	hindlimb movement	38220
@NP	a 21-point scale	38241
@NP	animals	38264
@NP	a 90-cm diameter open field	38291
@NP	The BBB rating scale	38320
@NP	ankle , knee and hip movements	38354
@NP	weight support and plantar	38400
@NP	weight support	38400
@NP	plantar	38419
@NP	limb movements , paw rotation and trunk stability	38461
@NP	limb movements	38461
@NP	paw rotation	38477
@NP	trunk stability	38494
@NP	Animals	38511
@NP	the first day	38536
@NP	contusion surgery	38556
@NP	consistency of the lesion	38586
@NP	consistency	38586
@NP	the lesion	38601
@NP	weekly	38636
@NP	Animals	38644
@NP	the study	38671
@NP	their BBB score at day 1	38684
@NP	their BBB score	38684
@NP	day 1	38703
@NP	greater than two standard deviations from the group mean	38713
@NP	greater than two standard deviations	38713
@NP	the group mean	38755
@NP	4.5.2	38771
@NP	Horizontal ladder	38778
@NP	test	38809
@NP	a more challenging assessment of hindlimb function rats	38818
@NP	a more challenging assessment	38818
@NP	hindlimb function rats	38851
@NP	a horizontal ladder	38894
@NP	apparatus	38927
@NP	the methods described by Metz and Whishaw -LRB- 2002 -RRB-	38943
@NP	the methods described by Metz and Whishaw	38943
@NP	the methods	38943
@NP	Metz and Whishaw	38968
@NP	2002	38986
@NP	Two 100-cm perspex sheets	38993
@NP	the side walls	39031
@NP	the apparatus	39049
@NP	10 cm	39087
@NP	their bases	39110
@NP	a series of 3 mm metal rungs set in an irregular pattern	39125
@NP	a series	39125
@NP	3 mm metal rungs set in an irregular pattern	39137
@NP	3 mm metal rungs	39137
@NP	an irregular pattern	39161
@NP	The ladder	39183
@NP	a height of 20 cm	39210
@NP	a height	39210
@NP	20 cm	39222
@NP	a mirror angled at 45 ° to provide a ventral view of the hindlimbs	39234
@NP	a mirror	39234
@NP	45 °	39253
@NP	a ventral view of the hindlimbs	39268
@NP	a ventral view	39268
@NP	the hindlimbs	39286
@NP	A dark home cage	39301
@NP	the end of the ladder	39335
@NP	the end	39335
@NP	the ladder	39346
@NP	locomotion	39370
@NP	Performance	39382
@NP	a 7 - category scale	39411
@NP	a 7	39411
@NP	category scale	39416
@NP	each step	39436
@NP	the foot placement on the rung	39446
@NP	the foot placement	39446
@NP	the rung	39468
@NP	the	39468
@NP	its position and placement accuracy	39500
@NP	0	39538
@NP	Total miss	39541
@NP	Total	39541
@NP	Deep	39557
@NP	slip ,	39562
@NP	slip	39562
@NP	Slight	39572
@NP	slip , -LRB- 3 -RRB- Replacement , -LRB- 4 -RRB-	39579
@NP	slip , -LRB- 3 -RRB- Replacement ,	39579
@NP	slip	39579
@NP	-LRB- 3 -RRB- Replacement	39585
@NP	4	39603
@NP	Correction , -LRB- 5 -RRB- Partial placement	39606
@NP	Correction	39606
@NP	-LRB- 5 -RRB- Partial placement	39618
@NP	Partial placement	39622
@NP	-LRB- 6 -RRB- Correct placement	39644
@NP	6	39645
@NP	Scores of 0 , 1 or 2	39667
@NP	Scores	39667
@NP	0 , 1 or 2	39677
@NP	` errors '' , i.e. an error represented a total miss or any type of foot slip	39703
@NP	` errors '' , i.e. an error represented a total miss	39703
@NP	` errors ''	39703
@NP	i.e. an error represented a total miss	39713
@NP	i.e.	39713
@NP	an error	39718
@NP	a total	39739
@NP	any type of foot slip	39755
@NP	any type	39755
@NP	foot slip	39767
@NP	The percentage of steps with errors	39778
@NP	The percentage	39778
@NP	steps with errors	39796
@NP	steps	39796
@NP	errors	39807
@NP	each animal	39833
@NP	3 passes of the apparatus	39852
@NP	3 passes	39852
@NP	the apparatus	39864
@NP	the group	39895
@NP	4.6	39906
@NP	Histological analysis Six weeks afterhOECtransplantation	39911
@NP	Histological analysis	39911
@NP	Six weeks	39933
@NP	each animal	39968
@NP	sodium pentobarbitone -LRB- Lethobarb ; 0.15 ml/100 g , IP -RRB-	39998
@NP	sodium pentobarbitone	39998
@NP	Lethobarb ; 0.15 ml/100 g , IP	40021
@NP	Lethobarb	40021
@NP	0.15 ml/100 g , IP	40032
@NP	0.15 ml/100 g	40032
@NP	IP	40047
@NP	physiological saline	40084
@NP	4 % paraformaldehyde in 0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	40118
@NP	4 % paraformaldehyde	40118
@NP	0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	40141
@NP	0.1 M phosphate buffer	40141
@NP	pH 7.4	40165
@NP	A segment of spinal cord extending 5 mm rostral and caudal to the injury site	40174
@NP	A segment	40174
@NP	spinal cord extending 5 mm rostral and caudal to the injury site	40187
@NP	spinal cord	40187
@NP	5 mm	40209
@NP	rostral and caudal to the injury site	40213
@NP	rostral and caudal	40213
@NP	the injury site	40235
@NP	The tissue	40266
@NP	the same fixative for 2 h	40295
@NP	the same fixative	40295
@NP	2 h	40317
@NP	a solution of 30 % sucrose	40347
@NP	a solution	40347
@NP	30 % sucrose	40361
@NP	0.1 M phosphate buffer	40376
@NP	0.01 % sodium azide until sectioning	40404
@NP	0.01 % sodium azide	40404
@NP	sectioning	40430
@NP	Sections	40442
@NP	a thickness of 30 μm	40463
@NP	a thickness	40463
@NP	30 μm	40478
@NP	the dorsal	40489
@NP	ventral surface of the spinal cord -LRB- approx 1.8 mm in total depth -RRB-	40503
@NP	ventral surface	40503
@NP	the spinal cord -LRB- approx 1.8 mm in total depth -RRB-	40522
@NP	the spinal cord	40522
@NP	1.8 mm in total depth	40546
@NP	1.8 mm	40546
@NP	total depth	40555
@NP	All the sections	40569
@NP	a series of 10	40602
@NP	a series	40602
@NP	10	40614
@NP	adjacent sections	40625
@NP	consecutive slides	40651
@NP	Each slide	40671
@NP	6 -- 7 sections of spinal cord	40702
@NP	6	40702
@NP	7 sections of spinal cord	40704
@NP	7 sections	40704
@NP	spinal cord	40718
@NP	300-μm intervals	40733
@NP	the dorsal to ventral surface	40755
@NP	the dorsal	40755
@NP	ventral surface	40769
@NP	each animal	40790
@NP	spinal cord sections	40803
@NP	the central canal	40856
@NP	each cord	40878
@NP	5 dorsal	40907
@NP	ventral sections	40919
@NP	some animals	40941
@NP	the very dorsal and/or the very ventral sections	40954
@NP	very dorsal	40958
@NP	the very ventral sections	40977
@NP	these	41024
@NP	the analysis	41049
@NP	One slide	41063
@NP	haematoxylin and eosin -LRB- H&E -RRB-	41090
@NP	haematoxylin and eosin	41090
@NP	H&E	41114
@NP	one	41120
@NP	Fluromount -LRB- Dako -RRB- for examination of hOECs	41139
@NP	Fluromount -LRB- Dako -RRB-	41139
@NP	Fluromount	41139
@NP	Dako	41151
@NP	examination of hOECs	41161
@NP	examination	41161
@NP	hOECs	41176
@NP	GFP	41193
@NP	Three other slides	41198
@NP	immunohistochemistry for GFAP , NF200 and ED1	41231
@NP	immunohistochemistry	41231
@NP	GFAP , NF200 and ED1	41256
@NP	Sections	41277
@NP	phosphate	41304
@NP	saline	41323
@NP	triton-X -LRB- PBST -RRB- for 10 min	41335
@NP	triton-X -LRB- PBST -RRB-	41335
@NP	triton-X	41335
@NP	PBST	41345
@NP	10 min	41355
@NP	5 % normal goat serum	41369
@NP	30 min	41394
@NP	overnight incubation in primary antibody	41408
@NP	overnight incubation	41408
@NP	primary antibody	41432
@NP	4 °C	41452
@NP	Rabbit anti-GFAP -LRB- 1/1000 , Dako , Denmark -RRB-	41458
@NP	Rabbit anti-GFAP	41458
@NP	1/1000	41476
@NP	Dako	41484
@NP	Denmark	41490
@NP	Mouse anti-Neurofilament 200 -LRB- 1/1000 , Sigma , MO -RRB-	41500
@NP	Mouse anti-Neurofilament 200	41500
@NP	Mouse	41500
@NP	200	41525
@NP	1/1000	41530
@NP	Sigma	41538
@NP	MO	41545
@NP	Rabbit anti-ED1 -LRB- 1/2000 , AbD Serotec , UK -RRB-	41553
@NP	Rabbit anti-ED1	41553
@NP	1/2000 , AbD Serotec , UK	41570
@NP	1/2000	41570
@NP	AbD Serotec , UK	41578
@NP	Sections	41596
@NP	3 changes of PBST	41620
@NP	3 changes	41620
@NP	PBST	41633
@NP	incubation	41645
@NP	AF 568-conjugated Goat	41666
@NP	anti-mouse IgG -LRB- 1/200 , Molecular Probes , Invitrogen , CA -RRB-	41689
@NP	anti-mouse IgG	41689
@NP	1/200	41705
@NP	Molecular Probes	41712
@NP	Invitrogen , CA	41730
@NP	TRITC-conjugated Swine	41750
@NP	1/200	41799
@NP	Dako	41806
@NP	Denmark	41812
@NP	1 h at room temperature	41825
@NP	1 h	41825
@NP	room temperature	41832
@NP	All sections	41850
@NP	Hoechst -LRB- 33342 , Invitrogen , CA -RRB- for 10 min	41888
@NP	Hoechst -LRB- 33342 , Invitrogen , CA -RRB-	41888
@NP	Hoechst	41888
@NP	33342	41897
@NP	Invitrogen	41904
@NP	CA	41916
@NP	10 min	41924
@NP	the cell nuclei	41944
@NP	Sections	41961
@NP	3 changes of PBST and cover	41990
@NP	3 changes	41990
@NP	PBST and cover	42003
@NP	Fluromount mounting	42032
@NP	media -LRB- Dako , Denmark -RRB-	42052
@NP	media	42052
@NP	Dako	42059
@NP	Denmark	42065
@NP	4.6.1	42075
@NP	Lesion size Low-power digital images of the H&E	42082
@NP	Lesion size Low-power digital images	42082
@NP	the H&E	42122
@NP	sections -LRB- Fig. 2 -RRB-	42138
@NP	sections	42138
@NP	Fig. 2	42148
@NP	injury quantification	42170
@NP	Each section	42193
@NP	a PixelLink video camera	42225
@NP	an Olympus BH-2 microscope	42261
@NP	One observer	42289
@NP	the group	42314
@NP	all the measurements	42329
@NP	Image J	42356
@NP	analysis software -LRB- Rasband , 1997 -- 2009 -RRB-	42364
@NP	analysis software	42364
@NP	Rasband , 1997 -- 2009	42383
@NP	Rasband	42383
@NP	1997 -- 2009	42392
@NP	The following measurements	42404
@NP	each horizontal section	42444
@NP	the spinal cord area , measured in a 5 mmlength of tissue	42469
@NP	the spinal cord area	42469
@NP	a 5 mmlength of tissue	42503
@NP	a 5 mmlength	42503
@NP	tissue	42519
@NP	the epicenter of the lesion	42537
@NP	the epicenter	42537
@NP	the lesion	42554
@NP	lines in Fig. 2	42579
@NP	lines	42579
@NP	Fig. 2	42588
@NP	the lesion area	42600
@NP	the area of extensive tissue disruption	42628
@NP	the area	42628
@NP	extensive tissue disruption	42640
@NP	loss of neurons	42669
@NP	loss	42669
@NP	neurons	42677
@NP	a rim of pale staining tissue	42690
@NP	a rim	42690
@NP	pale staining tissue	42699
@NP	lines in Fig. 2	42733
@NP	lines	42733
@NP	Fig. 2	42742
@NP	High power microscopy	42751
@NP	tissue injury	42792
@NP	cavity areas	42807
@NP	the lesion	42827
@NP	non-cellular areas selected by grey scale intensity using Image J software	42850
@NP	non-cellular areas	42850
@NP	grey scale intensity using Image J software	42881
@NP	grey scale intensity	42881
@NP	Image J software	42908
@NP	the width	42944
@NP	the spinal cord	42957
@NP	a line drawn perpendicular to the midline at the epicenter of the lesion	42976
@NP	a line	42976
@NP	the midline	43006
@NP	the epicenter of the lesion	43021
@NP	the epicenter	43021
@NP	the lesion	43038
@NP	the width	43053
@NP	tissue	43073
@NP	the same line	43083
@NP	the left and right sides	43112
@NP	Measurements	43145
@NP	the percentage of lesion area in the spinal cord area	43176
@NP	the percentage	43176
@NP	lesion area in the spinal cord area	43194
@NP	lesion area	43194
@NP	the spinal cord area	43209
@NP	the percentage of cavity area in the lesion area	43231
@NP	the percentage	43231
@NP	cavity area in the lesion area	43249
@NP	cavity area	43249
@NP	the lesion area	43264
@NP	the percentage of spared tissue in the width of the spinal cord	43285
@NP	the percentage	43285
@NP	spared tissue in the width of the spinal cord	43303
@NP	spared tissue	43303
@NP	the width of the spinal cord	43320
@NP	the width	43320
@NP	the spinal cord	43333
@NP	4.6.2	43350
@NP	Immunohistochemistry hOECs	43357
@NP	strong green fluorescence	43394
@NP	All other immunohistochemistry	43421
@NP	red fluorescent secondary antibodies	43474
@NP	GFAP staining intensity	43512
@NP	a mean grey scale value	43552
@NP	NIH Image	43582
@NP	The increase in GFAP intensity	43593
@NP	The increase	43593
@NP	GFAP intensity	43609
@NP	the lesion	43636
@NP	the mean grayscale value of GFAP staining	43667
@NP	the mean grayscale value	43667
@NP	GFAP staining	43695
@NP	the lesion	43721
@NP	the mean grayscale value of GFAP staining 5 mm distal	43743
@NP	the mean grayscale value	43743
@NP	GFAP staining 5 mm distal	43771
@NP	GFAP staining	43771
@NP	5 mm	43785
@NP	the lesion	43800
@NP	The percentage increase in GFAP intensity in each spinal cord	43812
@NP	The percentage increase	43812
@NP	GFAP intensity in each spinal cord	43839
@NP	GFAP intensity	43839
@NP	each spinal cord	43857
@NP	each group at each level of spinal cord tissue	43891
@NP	each group	43891
@NP	each level of spinal cord tissue	43905
@NP	each level	43905
@NP	spinal cord tissue	43919
@NP	Sections of uninjured spinal cord	43939
@NP	Sections	43939
@NP	uninjured spinal cord	43951
@NP	no differences	43980
@NP	GFAP staining intensity	43998
@NP	the section using this method	44029
@NP	the section	44029
@NP	this method	44047
@NP	Primary antibody	44060
@NP	negative controls	44093
@NP	Sections stained with NF200	44112
@NP	Sections	44112
@NP	NF200	44134
@NP	confocal microscopy	44160
@NP	hOECs	44196
@NP	NF 200 positive axon profiles	44225
@NP	NF 200	44225
@NP	Antibodies against ED1	44256
@NP	Antibodies	44256
@NP	ED1	44275
@NP	macrophage/microglia infiltration	44300
@NP	4.7	44335
@NP	Statistical methods	44340
@NP	the open field test , two way ANOVA	44364
@NP	the open field test	44364
@NP	two way ANOVA	44385
@NP	measures	44408
@NP	BBB scores	44437
@NP	the hOEC transplanted	44452
@NP	control groups over the 6-week period with Boneronni post hoc tests	44478
@NP	control groups	44478
@NP	the 6-week period with Boneronni post hoc tests	44498
@NP	the 6-week period	44498
@NP	Boneronni post hoc tests	44521
@NP	the horizontal ladder test and histological measurements	44551
@NP	the horizontal ladder test	44551
@NP	histological measurements	44582
@NP	t-tests	44609
@NP	the groups	44638
@NP	6 weeks post contusion	44652
@NP	6 weeks	44652
@NP	The statistical packages	44676
@NP	SPSS	44701
@NP	.0 -LRB- SPSS released 23/08/08 , Chicago , SPSS Inc. -RRB-	44709
@NP	.0	44709
@NP	SPSS released 23/08/08 , Chicago , SPSS Inc.	44713
@NP	SPSS	44713
@NP	23/08/08 , Chicago , SPSS Inc.	44727
@NP	23/08/08	44727
@NP	Chicago , SPSS Inc.	44737
@NP	Chicago	44737
@NP	SPSS Inc.	44746
@NP	Prism 5 -LRB- GraphPad Software , Inc , CA -RRB-	44761
@NP	Prism 5	44761
@NP	GraphPad Software	44770
@NP	Inc	44789
@NP	CA	44794
@NP	statistical analysis and α = 0.05	44812
@NP	statistical analysis and α	44812
@NP	0.05	44839
@NP	the criterion for statistical significance	44856
@NP	the criterion	44856
@NP	statistical significance	44874
@VP	assist in spinal cord repair and clinical trials	562
@VP	investigating the efficacy of hOECs in animal models of spinal cord injury	780
@VP	derived from biopsies of human olfactory mucosa	881
@VP	purifed by culture in a serum-free medium containing neurotrophin-3	930
@VP	containing neurotrophin-3	972
@VP	genetically labelled with EGFP	999
@VP	stored frozen	1035
@VP	frozen	1042
@VP	had greater functional improvement in their hindlimbs than controls	1306
@VP	assessed using open field -LRB- BBB scale -RRB-	1375
@VP	using open field -LRB- BBB scale -RRB-	1384
@VP	rung walking tests	1428
@VP	walking tests	1433
@VP	is unclear	1857
@VP	modulating inflammatory responses and reducing secondary damage to the cord	2009
@VP	modulating inflammatory responses	2009
@VP	reducing secondary damage to the cord	2047
@VP	1	2087
@VP	is limited capacity of the human spinal cord to repair itself	2421
@VP	to repair itself	2466
@VP	repair itself	2469
@VP	to protect and repair the injured spinal cord	2530
@VP	protect and repair the injured spinal cord	2533
@VP	share some properties with astrocytes and Schwann cells	2649
@VP	make them ideal candidates for cellular grafts into injured spinal tissue	2740
@VP	mimics aspects of many common human injuries	4290
@VP	obtained OECs from the olfactory bulbs within the cranial cavity	4400
@VP	to obtain the cells	4630
@VP	obtain the cells	4633
@VP	obtained from the olfactory mucosa in the nose -LRB- Bianco et al. , 2004 -RRB-	4663
@VP	derived from the olfactory mucosa	4863
@VP	affecting olfactory function -LRB- Feron et al. , 1998 -RRB-	5182
@VP	obtained from the human mucosa	5439
@VP	genetically labelled with green fluorescent protein	5474
@VP	are able to produce similar behavioural outcomes to that reported for rat OECs	5526
@VP	to produce similar behavioural outcomes to that reported for rat OECs	5535
@VP	produce similar behavioural outcomes to that reported for rat OECs	5538
@VP	reported for rat OECs	5583
@VP	has been documented	5661
@VP	been documented	5665
@VP	documented	5670
@VP	have been investigated	5768
@VP	been investigated	5773
@VP	investigated	5778
@VP	limits xenograft rejection of the hOECs	6112
@VP	delaying transplantation until a week after injury	6157
@VP	reduces exposure of the grafted cells to the acute inflammatory phase	6208
@VP	2	6280
@VP	improved locomotor behaviour	6326
@VP	using the BBB open field scores compared to controls -LRB- circles -RRB-	6478
@VP	repeated measures ANOVA , -LRB- F -LRB- 1,18 -RRB- = 9.6 , p = 0.006 -RRB-	6543
@VP	show significant increases in the OEC group by 4 weeks post injury	6620
@VP	shown as means and SEM	6840
@VP	stained	6964
@VP	shows the total area within which the spinal cord was quantified	7094
@VP	was quantified	7144
@VP	quantified	7148
@VP	dotted region	7168
@VP	shows the lesion area with cavities -LRB- * -RRB- and cell debris	7182
@VP	boxed areas in A and B.	7272
@VP	showing the peripheral white matter -LRB- wm -RRB-	7327
@VP	containing cell debris , macrophages , and trabeculae	7420
@VP	extending into the lesion -LRB- long arrows -RRB-	7489
@VP	transplanted animal	7571
@VP	Transplanted hOECs	7602
@VP	reduced lesion size , cavity area and increased tissue sparing	7621
@VP	reduced lesion size , cavity area	7621
@VP	increased tissue sparing	7658
@VP	expressed as percentages	7698
@VP	is highest in the dorsal spinal cord and transplanted hOECs	7828
@VP	reduced lesion size centrally	7888
@VP	was highest in the middle of the spinal cord and reduced in the hOEC	7957
@VP	reduced in the hOEC	8006
@VP	sparing	8084
@VP	increased from dorsal to ventral cord	8092
@VP	was differential sparing of tissue for the hOEC transplanted animals	8161
@VP	reduced the GFAP intensity adjacent to the lesion	8251
@VP	Transplanted hOECs	8321
@VP	remained within the lesion	8340
@VP	labelled hOECs	8447
@VP	dotted line	8550
@VP	seen in similar numbers in hOEC transplanted and control sections	8618
@VP	showing their morphology and rostro-caudal orientation	8740
@VP	surrounding the lesion	8855
@VP	dotted line shows lesion edge , solid line shows spinal cord edge	8879
@VP	shows lesion edge	8891
@VP	shows spinal cord edge	8921
@VP	viewed with -LRB- D -RRB- green filter only , -LRB- E -RRB- red filter only	8985
@VP	merged	9048
@VP	were also seen in the control sections	9233
@VP	seen in the control sections	9243
@VP	dotted line	9481
@VP	were seen in close proximity	9710
@VP	seen in close proximity	9715
@VP	closed arrow	9884
@VP	immunoreacted with ED1 to identify macrophages/microglia	10133
@VP	to identify macrophages/microglia	10156
@VP	identify macrophages/microglia	10159
@VP	do not display autofluorescence in the white matter	10387
@VP	display autofluorescence in the white matter	10394
@VP	receiving hOECs and 11 controls	10487
@VP	were used in the final analysis	10520
@VP	used in the final analysis	10525
@VP	was more than two standard deviations from the group mean	10683
@VP	was excluded due to post-operative complications	10756
@VP	excluded due to post-operative complications	10760
@VP	was 0.36 ± 0.02 m/s compared to 0.38 ± 0.04 m/s for the control group	10864
@VP	was no difference between the groups -LRB- t = 0.658 , df 18 , p = 0.52 -RRB-	10938
@VP	were comparable for the transplanted and non-transplanted group lesions	11022
@VP	increased during the 6-week post-contusion period to above baseline levels	11320
@VP	were spontaneously voiding urine by 2 weeks post-contusion surgery	11405
@VP	voiding urine by 2 weeks post-contusion surgery	11424
@VP	did not cause any noticeable adverse effects	11543
@VP	cause any noticeable adverse effects	11551
@VP	were alert , healthy and mobile after surgery	11637
@VP	were also p75 NTR immunoreactive	12049
@VP	indicating the culture	12147
@VP	was highly enriched for OEC	12170
@VP	enriched for OEC	12181
@VP	just prior to transplantation showed no expression of any of these markers	12240
@VP	addressed in Discussion	12328
@VP	is well known to occur in vitro	12460
@VP	known to occur in vitro	12468
@VP	to occur in vitro	12474
@VP	occur in vitro	12477
@VP	have used the term hOECs to describe these transplants	12662
@VP	used the term hOECs to describe these transplants	12667
@VP	to describe these transplants	12687
@VP	describe these transplants	12690
@VP	acknowledge their identity is unconfirmed	12722
@VP	is unconfirmed	12749
@VP	repeated measures , F -LRB- 1,18 -RRB- = 9.6 , p = 0.006	13041
@VP	show significant increases in the OEC group by 4 weeks post injury	13110
@VP	obtained by the hOEC transplanted animals at 6 weeks	13193
@VP	Rung walking test Six weeks after transplantation	13399
@VP	walking test Six weeks after transplantation	13404
@VP	crossing the horizontal ladder	13526
@VP	performed poorly in this task	13581
@VP	appeared more pronounced than in the open field test	13637
@VP	completing the task with many displaying spasms or jumps in movement	13725
@VP	many displaying spasms or jumps in movement	13750
@VP	completed after the rat	13853
@VP	had stabilised itself were scored	13877
@VP	stabilised itself were scored	13881
@VP	were scored	13899
@VP	scored	13904
@VP	Surrounding the lesion	14335
@VP	were identifiable by their smooth rounded appearance	14480
@VP	stained sections -LRB- Fig. 2C -RRB-	14566
@VP	had smaller lesions with less cavitation -LRB- Fig. 2B , E -RRB-	14720
@VP	sustained the most injury	14979
@VP	showed consistently smaller lesion sizes -LRB- Fig. 3A -RRB-	15179
@VP	did not migrate from the lesion into surrounding spinal cord tissue	16306
@VP	migrate from the lesion into surrounding spinal cord tissue	16314
@VP	surrounding spinal cord tissue	16343
@VP	showed an overall 17 % reduction in GFAP intensity in hOEC transplanted rats	16645
@VP	was consistent throughout the spinal cord	16925
@VP	showed significant differences -LRB- Fig. 3D -RRB-	17000
@VP	were seen migrating short distances towards the white matter	17227
@VP	seen migrating short distances towards the white matter	17232
@VP	migrating short distances towards the white matter	17237
@VP	were seen extending towards the centre of the lesion	17314
@VP	seen extending towards the centre of the lesion	17319
@VP	extending towards the centre of the lesion	17324
@VP	was also seen in trabeculae of tissue fragments within the lesion centre	17382
@VP	seen in trabeculae of tissue fragments within the lesion centre	17391
@VP	located in close proximity to axons at the caudal and rostral ends of the lesion	17578
@VP	continued into the epicentre	17682
@VP	appeared to be aligned in the same direction as axons	17722
@VP	to be aligned in the same direction as axons	17731
@VP	be aligned in the same direction as axons	17734
@VP	aligned in the same direction as axons	17737
@VP	was not possible to determine if hOECs were enwrapping axons	17892
@VP	to determine if hOECs were enwrapping axons	17909
@VP	determine if hOECs were enwrapping axons	17912
@VP	were enwrapping axons	17931
@VP	enwrapping axons	17936
@VP	Staining with ED1	18121
@VP	confirmed these were macrophages or microglia -LRB- Fig. 5F , G -RRB-	18181
@VP	were macrophages or microglia -LRB- Fig. 5F , G -RRB-	18197
@VP	3	18510
@VP	contused spinal cord of the rat	18687
@VP	reduced spinal cord lesion volume and reduced cavitation within the lesion	18901
@VP	reduced spinal cord lesion volume	18901
@VP	reduced cavitation within the lesion	18939
@VP	was also evidence for reduced astrogliosis at the lesion site	18983
@VP	used in this study	19094
@VP	are derived from the human olfactory mucosa	19113
@VP	derived from the human olfactory mucosa	19117
@VP	smooth muscle actin	19713
@VP	have not been verified independently	19842
@VP	been verified independently	19851
@VP	verified independently	19856
@VP	to unequivocally distinguish between OECs and Schwann cells in vitro	19913
@VP	distinguish between OECs and Schwann cells in vitro	19930
@VP	containing NT3 to selectively propagate OECs -LRB- Bianco et al. , 2004 -RRB-	20011
@VP	to selectively propagate OECs -LRB- Bianco et al. , 2004 -RRB-	20026
@VP	selectively propagate OECs -LRB- Bianco et al. , 2004 -RRB-	20029
@VP	recognises human myelinating Schwann cells -LRB- Levi et al. , 1994 -RRB-	20383
@VP	have referred to the transplanted cells as hOECs	20471
@VP	referred to the transplanted cells as hOECs	20476
@VP	consider these cell preparations to be highly enriched for OECs	20533
@VP	to be highly enriched for OECs	20566
@VP	be highly enriched for OECs	20569
@VP	highly enriched for OECs	20572
@VP	contain other , as yet unidentified , cell types from the olfactory mucosa	20633
@VP	grown under the same NT3 culture conditions	21098
@VP	maintained their GFAP +	21198
@VP	are very plastic in vitro	21274
@VP	have lost their immunological phenotype due to the particular protocol we used	21638
@VP	lost their immunological phenotype due to the particular protocol we used	21643
@VP	used	21712
@VP	are completely absent from the cell culture immediately prior to transplantation	21788
@VP	is made up entirely of a different cell population	21877
@VP	made up entirely of a different cell population	21880
@VP	located in the human olfactory mucosa	22020
@VP	is the case here	22067
@VP	demonstrated their potential for improving function after spinal cord injury	22134
@VP	improving function after spinal cord injury	22167
@VP	requires an accessible source of these cells	22241
@VP	were obtained from the rodent olfactory bulb	22323
@VP	obtained from the rodent olfactory bulb	22328
@VP	have been obtained from postmortem brain -LRB- Barnett et al. , 2000 -RRB-	22486
@VP	been obtained from postmortem brain -LRB- Barnett et al. , 2000 -RRB-	22491
@VP	obtained from postmortem brain -LRB- Barnett et al. , 2000 -RRB-	22496
@VP	is little morbidity	22704
@VP	were transplanted into the contusion model of spinal cord injury	22851
@VP	transplanted into the contusion model of spinal cord injury	22856
@VP	show interspecies differences in proliferation	23297
@VP	might be the different methods of cell culture used in different laboratories	23487
@VP	be the different methods of cell culture used in different laboratories	23493
@VP	used in different laboratories	23534
@VP	survived for 6 weeks in our study	23826
@VP	transplanted away from the lesion -LRB- Pearse et al. , 2007 -RRB-	24325
@VP	increased when co-cultured with acutely injured spinal cord explants	24464
@VP	co-cultured with acutely injured spinal cord explants	24479
@VP	expected	24657
@VP	occurred	24776
@VP	examined at deeper levels throughout the spinal cord	24793
@VP	spared tissue located ventrally as described by Basso	24931
@VP	described by Basso	24966
@VP	could sustain weight support in stance	25051
@VP	sustain weight support in stance	25057
@VP	stepping by 2 weeks after injury and this improved over the following 4 weeks	25125
@VP	improved over the following 4 weeks	25167
@VP	reflected in their higher BBB scores	25207
@VP	had more `` consistent '' hind-fore limb co-ordination	25271
@VP	located in this region	25850
@VP	containing the corticospinal and rubrospinal tracts	26528
@VP	appear to be markedly damaged in our injury model	26580
@VP	to be markedly damaged in our injury model	26587
@VP	be markedly damaged in our injury model	26590
@VP	leading to the locomotor improvements seen	26764
@VP	seen	26802
@VP	reduce lesion size and cavity area within the lesion	26927
@VP	described by others -LRB- Barakat et al. , 2005 ; Pearse et al. , 2007 -RRB-	27665
@VP	indicating that hOECs have ameliorated the injury-induced astrogliosis	27849
@VP	have ameliorated the injury-induced astrogliosis	27871
@VP	ameliorated the injury-induced astrogliosis	27876
@VP	obtained from the adult rat olfactory bulb	28203
@VP	shown here for hOECs from the olfactory mucosa	28285
@VP	also observed improved locomotor ability	28353
@VP	demonstrated significant axonal sparing	28398
@VP	were transplanted into the lesion site 7 days after the contusion	28462
@VP	transplanted into the lesion site 7 days after the contusion	28467
@VP	are the most common type of human injury	28633
@VP	descending or ascending axons	29185
@VP	was there evidence for axons coursing through the lesion/transplant site	29225
@VP	coursing through the lesion/transplant site	29254
@VP	released into the surrounding tissues	29407
@VP	involved in wound repair , extracellular matrix formation	29928
@VP	suggests another potential mechanism of action	30184
@VP	is an important process that removes cellular debris after injury	30304
@VP	removes cellular debris after injury	30333
@VP	left unresolved	30380
@VP	can continue to release toxic cytokines and destroy healthy tissue	30445
@VP	continue to release toxic cytokines and destroy healthy tissue	30449
@VP	to release toxic cytokines and destroy healthy tissue	30458
@VP	release toxic cytokines and destroy healthy tissue	30461
@VP	release toxic cytokines	30461
@VP	destroy healthy tissue	30489
@VP	leading to spreading secondary damage	30513
@VP	spreading secondary damage	30524
@VP	is a major problem following spinal cord injury -LRB- Fitch et al. , 1999 -RRB-	30557
@VP	is consistent with a reduced inflammatory response to the injury	30674
@VP	requires a deeper analysis of inflammatory cells and molecules	30753
@VP	reveal dynamic changes during the early stages and wound and repair responses	30969
@VP	injected animals , with significant improvements in function and tissue sparing	31210
@VP	4	31291
@VP	smodified Eagle 's medium/Ham F12 -LRB- DMEM/F12 ; JRH -RRB-	31925
@VP	were cultured as described	31984
@VP	cultured as described	31989
@VP	described	32001
@VP	was separated from the epithelium with a microspatula	32203
@VP	separated from the epithelium with a microspatula	32207
@VP	washed in Hank 's balanced salt solution -LRB- HBSS ; JRH -RRB-	32261
@VP	incubated in collagenase -LRB- 0.25 % ;	32457
@VP	dissociated into single cells by trituration and then washed in HBSS	32579
@VP	dissociated into single cells by trituration	32579
@VP	then washed in HBSS	32628
@VP	pelleted by centrifugation	32664
@VP	supplemented with foetal calf serum -LRB- FCS , 10 % -RRB-	32719
@VP	supplemented with neurotrophin-3	32948
@VP	enhances OEC proliferation	33041
@VP	overexpresses human recombinant green fluorescent protein -LRB- hrGFP -RRB-	33118
@VP	performed to isolate a near > 99 % pure population of cells expressing hrGFP	33379
@VP	to isolate a near > 99 % pure population of cells expressing hrGFP	33389
@VP	isolate a near > 99 % pure population of cells expressing hrGFP	33392
@VP	expressing hrGFP	33437
@VP	grown to approximately 80 - 90 % confluence	33481
@VP	followed by centrifugation to pelletise the cells	33655
@VP	to pelletise the cells	33682
@VP	pelletise the cells	33685
@VP	comprising of 90 % FCS and 10 % dimethyl sulfoxide -LRB- DMSO -RRB- at 4 °C	33766
@VP	dispensed into cryotubes -LRB- Nunc -RRB-	33878
@VP	placed immediately on ice	33914
@VP	being placed in liquid nitrogen for long-term storage	33947
@VP	placed in liquid nitrogen for long-term storage	33953
@VP	To revive cryopreserved cells	34002
@VP	revive cryopreserved cells	34005
@VP	removed from liquid nitrogen	34048
@VP	placed immediately into a 37 °C water bath	34081
@VP	was added drop-wise to a final volume of 1.5 ml	34190
@VP	added drop-wise to a final volume of 1.5 ml	34194
@VP	transferred slowly into 10 ml of prewarmed DMEM/F12 +10 % FCS	34268
@VP	centrifuged at 200g for 10 min	34332
@VP	cultured as previously described prior to use in transplantation experiments	34416
@VP	described prior to use in transplantation experiments	34439
@VP	to use in transplantation experiments	34455
@VP	use in transplantation experiments	34458
@VP	harvested	34668
@VP	counted using the vital dye Trypan Blue	34679
@VP	using the vital dye Trypan Blue	34687
@VP	dye Trypan Blue	34703
@VP	re-suspended at a concentration of 15 ×	34724
@VP	were obtained from the Animal Resources Centre -LRB- Perth , Australia -RRB-	34869
@VP	obtained from the Animal Resources Centre -LRB- Perth , Australia -RRB-	34874
@VP	equipped with an air filter and sterile beddingmaterials	34973
@VP	maintained on 12:12-h light	35034
@VP	maintained at 37 °C ± 1 °C	35426
@VP	was made in the dorsal midline skin from the mid to the low thoracic region	35465
@VP	made in the dorsal midline skin from the mid to the low thoracic region	35469
@VP	were separated to expose the spinal column	35595
@VP	separated to expose the spinal column	35600
@VP	to expose the spinal column	35610
@VP	expose the spinal column	35613
@VP	was performed on the T10 vertebrae	35663
@VP	performed on the T10 vertebrae	35667
@VP	developed at New York University -LRB- 12.5 mm , 10 g , -RRB-	35789
@VP	were recorded	35884
@VP	recorded	35889
@VP	calculated	35923
@VP	had a compression rate more than two standard deviations from the group mean	35977
@VP	were sutured closed in layers	36080
@VP	sutured closed in layers	36085
@VP	closed in layers	36093
@VP	were expressed manually until the normal voiding response returned	36334
@VP	expressed manually until the normal voiding response returned	36339
@VP	returned	36392
@VP	were continued until the urine was clear	36414
@VP	continued until the urine was clear	36419
@VP	was clear	36445
@VP	were re-anesthetized as above and the T10 lesion site re-exposed	36539
@VP	re-anesthetized as above and the T10 lesion site re-exposed	36544
@VP	re-exposed	36593
@VP	was stabilized using clamps to the T9 and T11 spinous process	36626
@VP	stabilized using clamps to the T9 and T11 spinous process	36630
@VP	using clamps to the T9 and T11 spinous process	36641
@VP	attached to a micromanipulater	36729
@VP	was used to inject hOECs in solution into the spinal cord lesion	36760
@VP	used to inject hOECs in solution into the spinal cord lesion	36764
@VP	to inject hOECs in solution into the spinal cord lesion	36769
@VP	inject hOECs in solution into the spinal cord lesion	36772
@VP	were suspended in 7 μl of DMEM/F12 + 10 % FCS	36849
@VP	suspended in 7 μl of DMEM/F12 + 10 % FCS	36854
@VP	was injected into the centre of the lesion over 5 min	36917
@VP	injected into the centre of the lesion over 5 min	36921
@VP	was injected 1 mm rostral	36976
@VP	injected 1 mm rostral	36980
@VP	was injected 1 mm caudal on the midline at a depth of 0.5 mm	37011
@VP	injected 1 mm caudal on the midline at a depth of 0.5 mm	37015
@VP	injected into the same sites	37150
@VP	were held in place for a further 3 min to reduce leakage on removal	37206
@VP	held in place for a further 3 min to reduce leakage on removal	37211
@VP	to reduce leakage on removal	37245
@VP	reduce leakage on removal	37248
@VP	familiarised with the open field apparatus	37320
@VP	pre-trained on the horizontal ladder prior to surgery	37367
@VP	were also tested on the horizontal ladder at 6 weeks post-contusion	37573
@VP	tested on the horizontal ladder at 6 weeks post-contusion	37583
@VP	linked to a FileMaker Pro database	37691
@VP	could be analysed frame by frame when necessary	37965
@VP	be analysed frame by frame when necessary	37971
@VP	analysed frame by frame when necessary	37974
@VP	were used as the final score for each trial	38030
@VP	used as the final score for each trial	38035
@VP	was used for open field assessments	38147
@VP	used for open field assessments	38151
@VP	move freely within a 90-cm diameter open field	38272
@VP	stepping	38427
@VP	coordinated limb movements , paw rotation and trunk stability	38449
@VP	to test for consistency of the lesion	38574
@VP	test for consistency of the lesion	38577
@VP	thereafter assessed weekly	38616
@VP	was greater than two standard deviations from the group mean	38709
@VP	rung walking test For a more challenging assessment of hindlimb function rats	38796
@VP	walking test For a more challenging assessment of hindlimb function rats	38801
@VP	using the methods described by Metz and Whishaw -LRB- 2002 -RRB-	38937
@VP	described by Metz and Whishaw	38955
@VP	separated by 10 cm	39074
@VP	connected at their bases	39097
@VP	set in an irregular pattern	39154
@VP	angled at 45 ° to provide a ventral view of the hindlimbs	39243
@VP	to provide a ventral view of the hindlimbs	39257
@VP	provide a ventral view of the hindlimbs	39260
@VP	was suspended at the end of the ladder to encourage locomotion	39318
@VP	suspended at the end of the ladder to encourage locomotion	39322
@VP	to encourage locomotion	39357
@VP	encourage locomotion	39360
@VP	was scored using a 7 - category scale	39394
@VP	scored using a 7 - category scale	39398
@VP	using a 7 - category scale	39405
@VP	rung	39472
@VP	miss	39547
@VP	-LRB- 5 -RRB- Partial placement	39618
@VP	represented a total miss	39727
@VP	miss	39747
@VP	was calculated for each animal during 3 passes of the apparatus	39814
@VP	calculated for each animal during 3 passes of the apparatus	39818
@VP	averaged for the group	39882
@VP	injected with sodium pentobarbitone -LRB- Lethobarb ; 0.15 ml/100 g , IP -RRB-	39984
@VP	perfused transcardially with physiological saline	40055
@VP	followed by 4 % paraformaldehyde in 0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	40106
@VP	extending 5 mm rostral and caudal to the injury site	40199
@VP	was collected	40251
@VP	collected	40255
@VP	fixed in the same fixative for 2 h	40286
@VP	mounted on a series of 10 so that adjacent sections were on consecutive slides	40591
@VP	were on consecutive slides	40643
@VP	were aligned anatomically using the central canal	40824
@VP	aligned anatomically using the central canal	40829
@VP	using the central canal	40850
@VP	was assessed using 5 dorsal to ventral sections	40888
@VP	assessed using 5 dorsal to ventral sections	40892
@VP	using 5 dorsal to ventral sections	40901
@VP	were not complete so these were excluded from the analysis	41003
@VP	were excluded from the analysis	41030
@VP	excluded from the analysis	41035
@VP	was stained with haematoxylin and eosin -LRB- H&E -RRB-	41073
@VP	stained with haematoxylin and eosin -LRB- H&E -RRB-	41077
@VP	mounted in Fluromount -LRB- Dako -RRB- for examination of hOECs expressing GFP	41128
@VP	expressing GFP	41182
@VP	were used for immunohistochemistry for GFAP , NF200 and ED1	41217
@VP	used for immunohistochemistry for GFAP , NF200 and ED1	41222
@VP	to visualize the cell nuclei	41931
@VP	visualize the cell nuclei	41934
@VP	were then rinsed in 3 changes of PBST and cover	41970
@VP	rinsed in 3 changes of PBST and cover	41980
@VP	slipped using Fluromount mounting	42018
@VP	using Fluromount mounting	42026
@VP	stained sections -LRB- Fig. 2 -RRB- were used for injury quantification	42130
@VP	were used for injury quantification	42156
@VP	used for injury quantification	42161
@VP	captured using a PixelLink video camera mounted on an Olympus BH-2 microscope	42210
@VP	using a PixelLink video camera mounted on an Olympus BH-2 microscope	42219
@VP	mounted on an Olympus BH-2 microscope	42250
@VP	made all the measurements using Image J	42324
@VP	using Image J	42350
@VP	were made on each horizontal section	42431
@VP	made on each horizontal section	42436
@VP	measured in a 5 mmlength of tissue	42491
@VP	thick dashed lines in Fig. 2	42566
@VP	thin dashed lines in Fig. 2	42721
@VP	were non-cellular areas selected by grey scale intensity using Image J software	42845
@VP	selected by grey scale intensity using Image J software	42869
@VP	using Image J software	42902
@VP	measured	42931
@VP	was	42940
@VP	drawn perpendicular to the midline at the epicenter of the lesion	42983
@VP	spared tissue on the same line as above , with the left and right sides summed	43066
@VP	summed	43137
@VP	exhibited strong green fluorescence	43384
@VP	was carried out using red fluorescent secondary antibodies	43452
@VP	carried out using red fluorescent secondary antibodies	43456
@VP	using red fluorescent secondary antibodies	43468
@VP	was measured as a mean grey scale value using NIH Image	43536
@VP	measured as a mean grey scale value using NIH Image	43540
@VP	using NIH Image	43576
@VP	divided by the mean grayscale value of GFAP staining 5 mm distal to the lesion	43732
@VP	was averaged for each group at each level of spinal cord tissue	43874
@VP	averaged for each group at each level of spinal cord tissue	43878
@VP	using this method	44041
@VP	was omitted for negative controls	44077
@VP	omitted for negative controls	44081
@VP	stained with NF200	44121
@VP	to determine if hOECs were co-localised with NF 200 positive axon profiles	44180
@VP	determine if hOECs were co-localised with NF 200 positive axon profiles	44183
@VP	were co-localised with NF 200 positive axon profiles	44202
@VP	co-localised with NF 200 positive axon profiles	44207
@VP	were used to confirm macrophage/microglia infiltration	44279
@VP	used to confirm macrophage/microglia infiltration	44284
@VP	to confirm macrophage/microglia infiltration	44289
@VP	confirm macrophage/microglia infiltration	44292
@VP	were used to compare the groups at 6 weeks post contusion	44617
@VP	used to compare the groups at 6 weeks post contusion	44622
@VP	to compare the groups at 6 weeks post contusion	44627
@VP	compare the groups at 6 weeks post contusion	44630
@VP	v17 .0 -LRB- SPSS released 23/08/08 , Chicago , SPSS Inc. -RRB-	44706
@VP	released 23/08/08 , Chicago , SPSS Inc.	44718
@VP	were used for statistical analysis and α = 0.05	44798
@VP	used for statistical analysis and α = 0.05	44803
@VP	was used as the criterion for statistical significance	44844
@VP	used as the criterion for statistical significance	44848
